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Abstract 
Cumulated scientific evidence suggests that the pathology causing Alzheimer's disease 
(AD) occurs many years or even decades before memory impairment and other clinical 
symptoms arise. Tangible and detailed knowledge about different pathological processes, 
their interactions, and time course is therefore of the essence both for the development of 
potentially successful treatments and a reliable early diagnosis of this relentless disorder. 
The past decade has thus seen an explosion in research on biomarkers that could provide in 
vivo evidence for these pathological processes, involving β-amyloid (Aβ) production and 
aggregation into plaques, neurofibrillary tangle formation, neuroinflammation, and 
eventually neurodegeneration. 
 The rare form of dominantly-inherited early-onset familial AD (eoFAD), with 
almost complete mutation penetrance and defined age of disease onset, has been proposed 
as a model to study the very early disease mechanisms that are also supposed to underlie 
the common sporadic form (sAD). However, more than 200 mutations in three different 
genes (PSEN1 and 2, APP) have been identified as causing eoFAD, some of which have 
been shown to differ substantially from others. 
 This work employed multi-tracer positron emission tomography (PET), using the 
tracers 2-[18F]‐fluoro-2‐deoxy‐D‐glucose (FDG), N-methyl-[11C] 2-(4'-
methylaminophenyl)-6-hydroxy-benzothiazole (PIB), and [11C]-L-deuterium-deprenyl 
(DED) to explore the characteristics, time course and interrelationship of cerebral glucose 
metabolism, fibrillar Aβ burden, and astrocyte activation (astrocytosis) at different pre-
symptomatic and symptomatic disease stages of eoFAD and sAD, in relationship to 
cognition, other AD biomarkers, and/or post-mortem pathology. 
 Thalamic hypometabolism in PSEN1 eoFAD mutation carriers was demonstrated 
in this thesis nearly 20 years before they were expected to develop clinical symptoms. The 
pattern of hypometabolism studied in several mutation carriers spread subsequently to 
regions that are also typically affected in sAD, correlating well with cognitive decline at 
symptomatic disease stages. Regional hypometabolism was furthermore found to correlate 
with typical AD pathology, namely neuritic Aβ plaques at post-mortem examination, 
suggesting that FDG PET is an excellent marker of disease progression from early pre-
symptomatic stages to terminal disease.  
 One particular eoFAD mutation, the Arctic APP mutation, has been reported to 
modify amyloid processing in a way that obviates the formation of fibrillar Aβ, the form of 
Aβ most prone to aggregate into neuritic plaques. In contrast to carriers of other eoFAD 
mutations and sAD patients, we found that carriers of the Arctic APP mutation showed no 
cortical PIB PET retention as a measure of fibrillar Aβ load, while Aβ and tau in cerebral 
spinal fluid and glucose metabolism, and in advanced disease also medial temporal lobe 
atrophy as measured by magnetic resonance imaging and cognition were clearly 
pathological and typical of AD. The findings imply that clinical AD can be caused by 
forms of Aβ, supposedly oligomeric or protofibrillar, which cannot be detected by PIB 
PET. 
 Very little is still known from in vivo studies about when and where in the brain 
neuroinflammation occurs in AD. Here, it could be shown that DED binding as a measure 
of astrocytosis was elevated in prodromal AD patients, whereas binding levels in AD were 
comparable to those in controls. PIB PET retention was increased and glucose metabolism 
decreased in both groups and there was no regional relationship between the three tracers, 
indicating that astrocytosis is an early phenomenon in AD that follows a different spatial 
   
and temporal pattern than Aβ plaque deposition and impaired synaptic activity as 
measured by glucose metabolism. 
 Multi-tracer PET is in this work proven to provide novel insights in eoFAD and 
sAD pathogenesis with processes such as astrocytosis and the potential role of different Aβ 
species. This knowledge is of significance for the understanding of disease mechanisms as 
well as the comparability of the purely genetic and the sporadic form of AD. 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
   
Sammanfattning	  på	  svenska	  
Forskning har visat att patologin som orsakar Alzheimers sjukdom (AD) inträffar många år 
innan de första kognitiva symptomen uppstår. Det är därför avgörande att öka förståelsen 
om den patologiska processen för att lyckas utveckla framgångsrik behandling och för att 
kunna ställa en tidig tillförlitlig diagnos. Under det gångna årtiondet har många nya 
biomarkörer upptäckts som påvisar tidiga patologiska förändringar, som bland annat beta 
amyloid (Aβ) produktion och aggregering till plack, formation av neurofibrillära nystan, 
neuroinflammation och slutligen neurodegenereration. 
 AD kan delas upp i den sporadiska och den familjära formen beroende på huruvida 
orsaken till sjukdomen är genetisk betingad eller inte. Den ovanliga dominant-nedärvda 
familjära formen av AD (eoFAD) som medför tidigt insjuknade, har föreslagits som en bra 
modell för att studera tidiga sjukdomsmekanismer som kan ligga bakom även sporadisk 
AD (sAD). Mer än 200 mutationer i tre olika gener, presenilin-1 (PSEN1), presenilin-2 
(PSEN2) och amyloid precursor protein (APP), orsakar eoFAD som i vissa fall skiljer sig 
väsentligt åt i bland annat sjukdomsförlopp. 
 I denna avhandling har vi använt oss av så kallad "multi-tracer" positron emission 
tomografi (PET), en molekylär imaging metod som kombinerar olika spårämnen för att 
kunna studera samband mellan fysiologiska och patologiska processer på molykär nivå. Vi 
använde spårämnena 2-[18F]‐fluoro-2‐deoxy‐D‐glucose (FDG), N-methyl-[11C] 2-(4'-
methylaminophenyl)-6-hydroxy-benzothiazole (PIB) och [11C]-L-deuterium-deprenyl 
(DED) för att studera glukosmetabolism, amyloida plack och astrocyt aktivering. Vi 
undersökte dessa processer för att utforska förhållandet mellan dem innan sjukdomen 
brutit ut och då symptom har börjat visa sig och diagnos har ställts i både eoFAD och sAD.  
 I den första studien har vi studerat bärare av en PSEN1 mutation och observerat 
nedsatt glukosmetabolism i en specifik region, thalamus, nästan 20 år innan förväntad 
ålder för insjuknande. Hypometabolismen spred sig sen till områden påverkade även i sAD 
och korrelerade väl med den kognitiva försämringen. Den regionala hypometabolismen 
upptäcktes även korrelera med antalet Aβ plack i samma område efter undersökning av 
dessa region efter patientens död. Detta visar att FDG PET är en bra markör för att följa 
sjukdomsutvecklingen från långt innan symptom visar sig ända till senaste 
sjukdomsskeden. 
 Denna avhandling har vidare studerat bärare av en annan eoFAD mutation i APP 
genen kallad den Arktiska mutationen. Denna mutation har rapporterats modifiera Aβ 
processningen så att ingen fibrillär Aβ med en viss struktur bildas vilket förhindrar 
aggregering till neuritiska plack. I motsats till bärare av andra eoFAD mutationer och i 
sporadisk AD, har vi upptäckt att bärare av den Arktiska mutationen inte visar något 
upptag av PIB PET i hjärnbarken samtidigt som andra biomarkörer såsom Aβ och tau i 
cerebrospinal vätskan, glukosmetabolism och atrofi i vissa delar av hjärnan visade typiska 
AD mönster. Våra upptäckter visar på att AD kan orsakas av inte bara fibrillär Aβ, utan 
även av andra former, sannolikt oligomera eller protofibrillära, som inte kan detekteras av 
PIB PET. 
 I den tredje studien har vi studerat neuroinflammation som fortfarande är tämligen 
outforskat in vivo. Vi använde oss av DED PET för att mäta astrocyt aktivering och fann 
förhöjd detektion hos patienter med mild kognitiv svikt som med all sannolikhet kommer 
att utveckla AD vilket förespråkar att astrocyt aktivering skulle vara ett tidigt fenomen i 
AD. 
   
 Sammanfattningsvis, PET tillhandahåller inblick i den patologiska processen i både 
eoFAD och sAD som är av stor vikt för att öka förståelsen av bakomliggande 
sjukdomsmekanismer och för att följa patologiska förändringar från långt före till efter 
insjuknande. 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
   
Abbreviations	  &	  Acronyms	  
	  
Aβ β-amyloid 
ACh Acetylcholine 
AChEI Acetylcholinesterase inhibitor 
AD Alzheimer’s disease 
ADAS-cog Alzheimer’s Disease Assessment Scale - cognitive subscale 
ApoE Apolipoprotein E 
APP Amyloid precursor protein 
CAA Cerebral amyloid angiopathy 
CMRglc Cerebral metabolic rate of glucose 
CNS Central nervous system 
CSF Cerebrospinal fluid 
DED [11C]-L-deuterium-deprenyl 
DLB Dementia with Lewy-bodies 
eoAD Early-onset Alzheimer’s disease 
eoFAD Early-onset familial Alzheimer’s disease 
FAD Familial Alzheimer’s disease 
FDG 2-[18F]‐fluoro-2‐deoxy‐D‐glucose 
fMRI Functional magnetic resonance imaging 
FTD Frontotemporal dementia  
loAD Late-onset Alzheimer's disease 
MCI Mild cognitive impairment 
MMSE Mini mental state examination 
MRI Magnetic resonance imaging  
MRS Magnetic resonance spectroscopy 
NFTs Neurofibrillary tangles 
NPs Neuritic plaques 
PDD Parkinson’s disease dementia 
PET Positron emission tomography 
PIB N-methyl-[11C] 2-(4'-methylaminophenyl)-6-hydroxy-benzothiazole (Pittsburgh 
Compound B) 
PSEN Presenilin 
sAD Sporadic Alzheimer’s disease 
SPECT Single photon emission computed tomography 
VAD Vascular dementia 
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  1 
Introduction	  
Alzheimer’s	  disease	  
When in 1901 the German psychiatrist and neuropathologist Alois Alzheimer first met 
Auguste Deter, a 51-year-old woman who described her strange state of delusion and 
forgetfulness with the words “I have lost myself”, he could hardly have imagined that this 
would be the beginning of more than a hundred years of effort and struggle against a 
relentless disease striking millions all over the globe. In his publication “Über eine 
eigenartige Erkrankung der Hirnrinde” [1], which alluded to a post-mortem examination of 
Auguste Deter’s brain, Alzheimer later described the still valid major hallmarks of what 
thereafter would be called Alzheimer’s disease (AD). 
AD is the most common form among a group of symptoms described as dementia, 
accounting for between 50 and over 70% of all cases [2]. Apart from AD, this syndrome 
includes disorders such as frontotemporal dementia (FTD), cerebrovascular dementia 
(VAD), dementia with Lewy-bodies (DLB), and Parkinson’s disease dementia (PDD). 
With an estimated 29 million patients suffering from dementia worldwide in 2005, it 
ranks among the major causes of death and constitutes a considerable economic burden 
which has been calculated to approximate US$ 315 billion [3]. The prevalence of dementia 
is closely related to age, with a rate of only 1% in 60- to 64-year-olds, but up to 33% in 
individuals aged 85 years or older [4]. Given the global increase in life expectancy, the 
prevalence of AD has also been predicted to rise globally to 80 million patients within the 
next 40 years [5]. 
AD is a lethal, progressive neurodegenerative disorder that leads to a clinical 
picture of gradually deteriorating memory with subsequent appearance of other cognitive, 
behavioural, and neuropsychiatric changes that impair social interactions and activities of 
daily living, until the afflicted person is completely dependent on caregivers [6]. The 
inexorable disease progression thereby puts immense pressure on AD patients' families and 
their social environment. 
Typically, individuals with AD can be subdivided into cases of sporadic AD (sAD) 
(sporadic: “occurring in irregular or random instances” [7]), and familial AD (FAD), with 
sAD accounting for the vast majority of all AD cases. 
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Figure	   1.	  Characteristic	   AD	   pathology.	   (A)	   Atrophy	   of	   the	   brain	   as	   visualised	   by	  magnetic	   resonance	  
imaging.	   (B)	  Neuritic	  plaques	   (green	  arrow)	  and	  neurofibrillary	   tangles	   (red	  arrow)	  as	   seen	  under	   the	  
microscope	   (Bielschowsky	   staining).	   The	   small	   window	   shows	   intense	   cortical	   plaque	   pathology	  
(Microscopy	  images	  courtesy	  of	  Dr	  Nennesmo,	  Karolinska	  University	  Hospital	  Huddinge).	  
	  
A further subdivision can be made into those who develop symptoms under the age of 65, 
early-onset AD (eoAD), and the far more common form that develops at ages over 65, 
late-onset AD (loAD). Only about 1% of all AD patients belong to the specific subgroup 
of early-onset familial AD (eoFAD) which is caused by autosomal-dominant gene 
mutations [8]. The terms FAD and eoAD may describe eoFAD, but may also include sAD 
cases with a family history of the disease or AD associated with non-dominant genetic 
factors such as the apolipoprotein (APOE) ε4 allele. 
  3 
Pathology	  and	  pathogenesis	  
When Dr Alzheimer examined Auguste Deter's autopsied brain, he found substantial 
shrinkage (atrophy) of the brain macroscopically and, under the microscope, two of the 
most typical hallmarks of AD: extracellular senile or neuritic plaques and intracellular 
neurofibrillary tangles (NFTs) (Figure 1) [1]. With increasing scientific knowledge, 
however, many more pathological features of AD such as neuroinflammatory processes 
have been discovered and described. 
	  
β-­‐Amyloid	  
A crucial finding was made in the 1980s, when a fibrillar, insoluble form of the β-amyloid 
(Aβ) protein was identified as the main component of the neuritic plaque cores [9, 10]. Aβ 
was originally believed to be exclusively formed under pathological conditions. At the 
beginning if the 1990s, however, it was reported to be derived under physiological 
conditions by proteolytic cleavage from its precursor, amyloid precursor protein (APP) [11, 
12]. APP is a ubiquitously expressed, type 1 integral membrane protein that exists 
predominantly as three different isoforms: APP695, APP751, and APP770, whereof 
APP695 is the most abundant isoform in the brain [13]. Three enzymes were found to 
account for APP proteolysis and were subsequently denominated α-, β-, and γ-secretase. 
These cleave APP in either of two exclusive ways, a non-amyloidogenic (or α-secretase) and 
an amyloidogenic (or β-secretase) pathway (Figure 2). 
 The non-amyloidogenic pathway first involves α-secretase cleavage of APP within 
the Aβ domain, resulting in the soluble α-APPs fragment, followed by γ-secretase cleavage 
of the remaining C-terminal fragment (α-CTF or C83), which releases a peptide called p3 
and the APP intracellular C-terminal domain (AICD) [14-17]. The amyloidogenic 
pathway, however, results in release of Aβ peptides of different lengths [18, 19]. First, APP 
is cleaved by β-secretase (BACE1) at the β-site (N-terminal position 1), forming the 
soluble fragment β-APPs [20]. The remaining β-CTF (C99) is then cleaved by γ-secretase 
at different sites, releasing Aβ peptides of 39–43 amino acids in length. Under 
physiological conditions, Aβ1-40 and Aβ1-42 form the majority of peptides, with Aβ1-40 being 
by far the most abundant [9, 21]. The hydrophobic, fibrillogenic Aβ1-42 species aggregates 
more readily than other species into soluble oligomers, protofibrils, and eventually 
insoluble fibrils characterised by a β-pleated sheet conformation, which stains with Congo 
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Figure	  2.	  Amyloidogenic	  and	  non-­‐amyloidogenic	  metabolism	  of	  APP.	  
 
red and Thioflavin-S, eventually forming the AD-typical neuritic plaques [21, 22]. Besides 
Aβ1-40/42, N-terminal truncated Aβ peptides such as Aβ3-40/42, Aβ11-40/42 and Aβ17-40/42, and 
several other proteins accumulate within these plaques. When Aβ is deposited in non-
fibrillar (non-β-sheet) conformations, it forms so-called diffuse plaques. Aggregates of Aβ 
can furthermore be found in blood vessel walls in many AD cases, a phenomenon called 
cerebral amyloid angiopathy (CAA) [23]. 
Physiologically, Aβ can be degraded by numerous enzymes. The most extensively 
studied are insulin-degrading enzyme and neprilysin – their levels have been demonstrated 
to be reduced in AD [24]. Likewise, clearance of Aβ from the central nervous system has 
been shown to be decreased in AD patients [25]. 
 The majority of Aβ plaques are found in the grey matter of the brain. Progression 
of amyloid plaque pathology generally proceeds in a particular manner, and depending on 
the brain regions affected this can be roughly classified into three widely recognised stages 
(A-C), as first proposed by Braak and Braak in 1991 [26, 27], or somewhat more precisely 
into five phases, as proposed by Thal, Braak, and colleagues in 2002 [28]. At Braak stage 
A, low densities of Aβ deposits are found in the basal neocortex of the temporal lobe. Stage 
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B shows an increase in Aβ deposits in almost all isocortical association areas and only the 
primary sensory areas and primary motor field remain almost devoid of deposits. There is 
mild involvement of the hippocampal formation, and Aβ may be found in the entorhinal 
cortex. Stage C is mainly characterised by virtually all isocortical areas being affected [27]. 
 The finding that Aβ deposition follows a hierarchical pattern in the medial 
temporal lobe (MTL) [29] led to a thorough examination of the hierarchical pattern of Aβ 
deposition in the entire brain. Phase 1 was described as pure neocortical Aβ deposits, while 
Phase 2 involves additional allocortical brain regions. Phase 3 involves Aβ deposits in 
diencephalic nuclei, the putamen, the caudate nucleus, and several cholinergic nuclei of the 
basal forebrain; brainstem nuclei are first affected in Phase 4. In Phase 5, additional brain 
stem nuclei and the cerebellum are finally affected [28]. 
 Aβ plaque burden and cognitive impairment have been reported to correlate only 
weakly or not at all [30-32]. Likewise, neither clinical disease nor specific functional 
impairment has been shown to correlate well with Aβ deposition [33, 34]. 
 The seminal discovery that mutations in the gene encoding APP could cause AD 
(see also "Genetics"), led to articulation of the amyloid cascade hypothesis (Figure 3) by 
Hardy and Higgins in 1992, which posits that an imbalance between deposition and 
clearance of Aβ in the brain is the central event in AD pathogenesis, initiating other 
pathological events until the manifestation of AD dementia [35]. The hypothesis has been 
massively criticised [36] and been subject to many modifications, but it is undoubtedly the 
predominant hypothesis in AD research and has been agenda-setting in drug development. 
In its beginnings, it was believed that the fibrillar, insoluble Aβ plaques were the cause of 
the disease [35]. Since then, the most substantial revision has been the inclusion of a 
concept that states that non-fibrillar (or pre-fibrillar) soluble Aβ oligomers are the most 
toxic species [37, 38]. Early evidence that these forms might play a role in memory 
impairment came from human brain tissue analyses that showed significant correlations 
between cortical levels of soluble Aβ and cognitive impairment as well as with the extent of 
synaptic loss [39, 40]. Numerous studies in vitro and in vivo in transgenic animal models 
have in fact confirmed that these soluble oligomeric Aβ or protofibrillar intermediate 
species and synthetically assembled Aβ-derived diffusible ligands (ADDLs) decrease or 
block long-term potentiation (LTP), a mechanism considered to underlie aspects of 
learning and memory, and to cause neuronal loss, as well as induction of an inflammatory 
response [41-45]. 
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Figure	  3.	  According	  to	  the	  amyloid	  cascade	  hypothesis,	  accumulation	  of	  Aβ	   is	  the	  central	  event	   in	  AD	  
pathogenesis,	   leading	   to	   NFT	   formation,	   triggering	   inflammatory	   processes,	   and	   causing	   synaptic	  
dysfunction	  and	  neurodegeneration	  until	  cognitive	  deficits	  result	  in	  dementia.	  
	  
A differing pattern of oligomer species has been identified in a recent study of human post-
mortem brain tissue between eoAD and loAD [46]. 
 Of note is the fact that the term soluble Aβ is an operational definition, including 
all forms of Aβ that remain in solution following high-speed centrifugation of brain 
extracts. These have exclusively been studied in artificial environments and have not yet 
been shown to occur in vivo. 
	  
Tau	  
Shortly after Aβ was discovered to be the main component of neuritic plaques, 
neurofibrillary tangles (NFTs) were shown to consist of the hyperphosphorylated form of a 
neuronal microtubule-associated protein called tau [47]. Tau is mainly found in axons but 
can also occur at much lower levels in dendrites, exerting functions that are not completely 
understood [48-50]. The best-established biological functions are the stabilisation of the 
microtubule network and the regulation of axonal transport [51, 52]. 
In AD (and other so-called tauopathies), tau pathology is characterised by the 
somatodendritic accumulation of hyperphosphorylated tau, which eventually aggregates 
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into NFTs [53]. The phosphorylation of tau depends on the balance between different 
kinases and phosphatases [54]. Disruption of this balance as seen in AD leads to the 
sequestration of tau, which aggregates into insoluble tangles, causing microtubule 
disassembly and subsequent impairment of axonal transport, and synaptic and neuronal 
integrity [54]. 
 If tau hyperphosphorylation and accumulation are a cause or a consequence of AD 
is still an unsolved issue. According to the amyloid cascade hypothesis, tau pathology is 
driven by Aβ formation (see "Pathology: β-Amyloid"). A recent publication concerns three 
possible modes of interaction between Aβ and tau pathology, mainly based on findings in 
transgenic animal models. These suggest that (A) Aβ either actually triggers tau pathology, 
(B) tau mediates the toxic effects of Aβ, or that (C) Aβ and tau have synergistic toxic 
effects on different components of the same system, exemplified by their effects on 
mitochondrial respiration [52]. 
 The deposition of AD-related NFTs pathology follows a certain hierarchical 
pattern, which differs fundamentally from Aβ deposition. It was originally categorised by 
Braak and Braak into six stages in 1991 [26]. To enhance accuracy of the staging and meet 
the demands of clinical routine, these stages were re-evaluated using much thinner sections 
and improved staining [55]. The first stage involves lesions in the transentorhinal regions; 
in stage II these lesions extend into the entorhinal region, and in stage III further into 
neocortical areas of the fusiform and lingual gyri. From there, tau pathology spreads more 
widely into neocortical association areas (stage IV), frontal, superolateral, and occipital 
neocortex (stage V), and finally most areas of the neocortex are affected (stage IV). In the 
final stages (V and VI), a 91% agreement on the diagnosis of AD was reached within the 
BrainNet Europe Consortium, while milder lesions (stages I and II) led to a more diverse 
judgement [56]. 
 The patterns of Aβ plaques and tau pathology differ not only spatially but also 
temporally. Tau pathology has consistently been reported to precede Aβ deposition [27, 
57] and to correlate far better with cognitive impairment and thus clinical disease [32, 58]. 
Interestingly, pretangle tau material has been found in the majority of brains from a group 
of individuals aged 4 to 29 in the absence of Aβ protein deposition [59]. Here, pathology 
started in subcortical, non-thalamic nuclei in most of the examined cases, which further led 
to the hypothesis that tau pathology may spread from there via neuron-to-neuron 
propagation [60]. 
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Neuroinflammation	  
Inflammation is the immune response of an organism towards harmful agents or events. 
An immune response is carried out by specialised cells that under physiological conditions 
may exert a wide variety of other functions. Inflammatory processes are crucial and 
necessary but can turn harmful e.g. in their chronic stages. Neuroinflammation, a localised 
inflammatory response in the CNS, is a prominent feature of AD but as with many aspects 
of AD pathology, we still do not know whether inflammatory processes represent a driving 
force for or a consequence of other pathology. Brain resident cells, namely microglia, 
astrocytes, and neurons, mediate neuroinflammatory processes. Early findings of activated 
microglia in neuritic plaques from AD brains led to the assumption of an inflammatory 
component being involved in AD pathogenesis [61]. This idea was confirmed by the fact 
that treatment with non-steroidal anti-inflammatory drugs (NSAIDs) had been shown to 
lower the risk of developing AD [62, 63]. 
 Microglia are cells related to the mononuclear phagocytic system, expressing 
proteins typical of phagocytic cells such as the major histocompatibility complex (MHC) 
and complement components [64]. When resting, they appear in a typical ramified shape, 
extending their processes into the surroundings in order to detect abnormalities [65]. On 
activation, microglia turn into more motile amoebic cells [66], releasing inflammatory 
mediators including neurotoxic cytokines such as interleukins and tumour necrosis factor α 
(TNF-α)  [67]. As mentioned above, microglia can often be found in or around neuritic, 
not diffuse plaques [68]. Aβ can trigger activation of microglia, which in a reciprocal 
manner, mediated by interleukins, increases the production of APP and its secreted 
fragments [69, 70]. This vicious circle might contribute to the chronic neuroinflammation 
in AD. 
 Astrocytes are the most abundant and diverse cell type in the brain. They appear in 
manifold morphological shapes and are organised in a huge network that involves 
connections of a single astrocyte with hundreds of neurons and thousands of synapses, as 
well as gap junctions between individual astrocytes [71]. Amongst the large variety of 
functions carried out by astroglial cells, maintenance and support of neuronal functions 
and physiology, formation of the blood-brain barrier, and clearance of neurotransmitters 
from the synaptic cleft could be considered most notable. Their role in brain energy 
homeostasis and metabolism is of particular interest as regards molecular imaging of 
cerebral glucose metabolism by means of positron emission tomography [72, 73] (see 
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"PET in AD: Glucose metabolism"). Close neuronal-astrocytic metabolic coupling, 
represented by astrocytic provision of lactate to neurons, has also been shown to be of 
importance with regard to memory formation [74], a process profoundly impaired in AD, 
and it affects neuronal integrity in the presence of Aβ aggregates [75]. 
 AD brains show prominent astrogliosis, predominantly around Aβ plaques [76-
78]. Aβ has been found in astrocytes surrounding neuritic plaques, recently also in the 
form of Aβ protofibrils [79-81]. Of note is the fact that astrocytes have been shown to 
participate both in the formation of Aβ plaques and in Aβ clearance [82-84]. The fact that 
(activated) astrocytes express β-secretase underlines their potentially important role in Aβ 
pathogenesis [85]. Other aspects of AD pathology might also be partly mediated by 
astrocytes. Parallel to hypertrophic astrogliosis close to neuritic plaques, astroglial atrophy 
distant from the plaques has been found in transgenic mice, leading to impaired astrocytic 
support for synaptic processes [84]. The degeneration of astrocytes hereby preceded the 
formation of both plaque and tangle pathology. 
 
Genetics	  
Early-­‐onset	  familial	  AD	  
Genetic predisposition is a well-known risk factor and cause of AD, as family histories 
involving early age at onset (younger than 65 years) and a clear autosomal dominant 
pattern of inheritance with virtually 100% penetrance were recognised as early as in the 
1930s [86]. It has been speculated that Auguste Deter, the first reported AD case, was part 
of a Volga-German family harbouring an autosomal dominant AD mutation and thus 
suffered from eoFAD [87]. Mutations in three genes — the β-amyloid precursor protein 
gene (APP) on chromosome 21 [88], the presenilin 1 gene (PSEN1) on chromosome 14 
[89], and the presenilin 2 gene (PSEN2) on chromosome 1 [90, 91] — have been found to 
be direct causes of eoFAD. PSEN1 mutations have been estimated to account for 80 - 90% 
of all eoFAD cases. The phenotypes associated with these mutations show early onset of 
the disease with a specific age at onset for a given pedigree. Several families harbouring 
eoFAD mutations have been discovered in Sweden, these are listed in Table 1. 
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Mutation	   Mean	  expected	  age	  of	  disease	  onset	  (y)	  
PSEN1	  Ile143Thr	   34	  
PSEN1	  Met146Val	   37.7	  
PSEN1	  His163Tyr	   54.2	  
PSEN1	  Arg269His	   55.1	  
APP	  KM670/671NL	  (Swedish	  APP)	   55	  
APP	  Glu693Gly	  (Arctic	  APP)	   59.7	  
	  
Table	  1.	  EoFAD	  mutations	  identified	  in	  Swedish	  pedigrees.	  
	  
APP 
Since the Aβ peptide was isolated from plaque cores from patients with AD and from 
patients with Down's syndrome (trisomy of chromosome 21) [92], the search for a gene 
encoding Aβ was initially focused on chromosome 21. In 1991, Hardy and colleagues 
identified a missense (point) mutation in the APP gene (APP) in kindred with linkage to 
chromosome 21 markers - the link between AD, Aβ and genetics was established [88]. 
Following this initial discovery, 31 dominant pathogenic APP missense mutations and 
APP locus duplications have been found to date, accounting for an estimated 16% of all 
eoFAD cases [www.molgen.ua.ac.be/admutations, [93]. In addition, two recessive APP 
mutations have recently been identified [94, 95]. All missense mutations are located 
around or within the Aβ sequence. Mutations outside Aβ often lie clustered in close 
proximity to β- and γ-secretase cleavages sites and exert their pathogenic effect by 
influencing the activity of these secretases. These mutations alter Aβ production depending 
on their position, commonly resulting in increased Aβ production or increased ratios of 
Aβ1-42/40 [96]. 
 Intra-Aβ mutations (Figure 4), in particular those close to the α-secretase cleavage 
site, seem to alter the Aβ sequence in a way that enhances its propensity to aggregate or 
result in protofibrillar Aβ formation [96]. Of these, only the Arctic APP (APParc) 
mutation causes AD in a dominant manner. APParc has been shown to enhance protofibril 
formation and has demonstrated plaque pathology without Congo red-positive Aβ cores in 
post-mortem examination [97, 98]. The A673V and the Osaka mutations cause AD in a 
recessive manner. Both show effects on Aβ production in accordance with their position; 
A673V enhances Aβ production, while the Osaka mutation enhances oligomerisation 
without fibrilisation [94, 95]. 
  11 
	  
Figure	  4.	  Location	  of	  intra-­‐Aβ	  APP	  mutations	  and	  the	  Swedish	  APP	  double	  mutation.	  
	  
	  
PSEN1 and 2 
Four years after the discovery of APP, genes on chromosome 14 and chromosome 1 were 
linked to familial AD and subsequently called presenilin 1 (PSEN1) and presenilin 2 
(PSEN2) [89, 91]. Ever since, over 170 pathogenic PSEN1 and 14 PSEN2 mutations have 
been identified. Both genes have a very similar genetic structure, encoding two highly 
homologous proteins. PSENs constitute one of four components of y-secretase, a major 
player in Aβ generation. PSEN mutations cause alterations in the y-secretase cleavage site, 
commonly resulting in increased Aβ1-42/40 ratios [96]. Interestingly, a dichotomous 
phenotype depending on the position of a certain mutation has been described. Mutations 
before codon 200 seem to be associated with younger age of onset and somewhat different 
pathology than mutations occurring beyond that point [99]. 
	  
Sporadic	  AD	  
Several susceptibility genes have also been identified in connection with sAD. The most 
consistently associated is ApoE, encoding apolipoprotein E, which is involved in cholesterol 
metabolism. ApoE exists in three isoforms ε2, ε3, and ε4. The ε4 allele, by unknown 
mechanisms, appears to shift age of onset towards an earlier age and increases the risk of 
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developing AD. Heterozygous carriers of this allele have been shown to have a threefold 
risk, and homozygous carriers even up to a 15-fold risk of developing AD in comparison 
with ε3 homozygotes [100]. 
 The four genes described so far have been estimated to account for less than 30% 
of the genetic variance in eoFAD and sAD/loAD [101]. The search for further genetic 
factors has identified several candidates, for example, SORL1, which has been found to 
cause loAD [102]. 
 
Clinical	  diagnosis	  
Dementia is commonly classified by using the criteria of the Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition (DSM-IV) [103]. AD can at present only be 
diagnosed definitively post-mortem by histological confirmation. A clinical diagnosis can 
thus only be probable AD. For that, a history of the time course and character of 
symptoms is taken from the patient or the patient’s social environment to assess whether 
cognitive or other instrumental functions are impaired and neuropsychological 
assessment is performed. The diagnosis is then made on the basis of criteria outlined by 
the National Institute of Neurologic and Communicative Disorders and Stroke – 
Alzheimer's Disease and Related Disorders Association (NINCDS–ADRDA) [104] 
according to which the diagnosis is classified as possible (atypical clinical features but no 
alternative diagnosis apparent without histological confirmation), probable (typical 
clinical syndrome without histological confirmation), or definite (clinical diagnosis with 
histological confirmation). Clinical AD diagnosis based on these criteria has proven 
sensitivity (distinguishing between AD patients and non-demented subjects) and 
specificity (distinguishing between AD and other forms of dementia) varying from 65% 
to over 80% and 23–88%, respectively [105, 106]. 
Several tools are used to stage AD in a clinical setting, such as the Mini Mental 
State Examination (MMSE) [107], the Clinical Dementia Rating (CDR) scale [108], and 
the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog). The MMSE 
consists of a set of 30 items dealing with orientation, calculation, memory function, 
language abilities, attention and visuospatial function and provides a rough measure for a 
classification into no dementia, mild dementia, and moderate dementia [109, 110]. 
The CDR scale rates impairment in six functional categories (memory, orientation, 
judgement and problem-solving, community affairs, home and hobbies, and personal care) 
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on a five-point scale. The rating stretches from CDR 0 (no dementia), over CDR 0.5 
(questionable dementia), CDR 1 (mild dementia), and CDR 2 (moderate dementia) to 
CDR 3 (severe dementia) [111]. 
The ADAS-cog is a more complex scale tapping eleven items that assess 
impairment of memory, language and praxis on a range of scores from 0 to 70 scores [87]. 
It is considered to be a thorough brief exam for the study of memory and language skills 
and therefore frequently used as a primary outcome measure in treatment trials in patients 
with mild to moderate AD [112, 113]. The results of a recent study suggested the use of 
sub-settings with different combinations of ADAS-cog test items to improve sensitivity to 
treatment effects [113]. 
Nowadays, the clinical diagnosis of AD is increasingly assisted by the use of several 
biomarkers; this is discussed in detail below (see "Biomarkers" and “Revision of diagnostic 
criteria”). 
	  
Neuropsychological	  assessment	   	   	   	   	   	  
In addition to the previously described rather unspecific assessments, numerous 
neuropsychological tests are applied to pinpoint impairment in different cognitive 
domains. Differences between normal aging and AD are especially obvious in episodic 
memory, semantic knowledge, and executive functions, but the syndrome of dementia also 
involves deficits in language, abstract reasoning, attention, and visuospatial abilities [114, 
115]. Of the above, episodic memory is impaired earliest in AD [116]. This domain is 
heavily dependent on the functionality of brain structures in the medial temporal lobe, 
which are commonly affected by AD pathology in very early disease stages [26, 117]. 
 No consensus has been reached on internationally standardised test batteries for 
neuropsychological testing in AD. However, in an attempt to systematise the assessment of 
patients and cognitively healthy individuals across the American Alzheimer's Disease 
Centers (ADC), the National Institute on Aging (NIA) recently designed a proposal for a 
uniform neuropsychological test battery [118]. This battery evaluates dementia severity by 
MMSE [107], attention by Digit Span (Wechsler Adult Intelligence Scale-Revised, WAIS-
R [119]), processing speed by Digit Symbol (WAIS-R) and Trail Making Test A [120], 
executive function by Trail Making Test B [120], memory by Logical Memory, Story A, 
Immediate and Delayed Recall (WAIS-R), and language abilities by animal and vegetable 
list generation, and the Boston Naming Test [121]. 
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Mild	  cognitive	  impairment	  
Mild cognitive impairment (MCI) is a more advanced form of age-related cognitive decline 
in which people notice subjective memory problems, and neuropsychological tests often 
confirm problems with delayed recall, although non-memory-related cognitive domains 
may also be impaired [122, 123]. The term MCI was introduced in 1988 but its definition 
has ever since been revised to characterise the subtle differences between MCI and early 
dementia, focussing on the fact that MCI describes a heterogeneous group of patients and 
that not all forms of MCI may convert to AD [123-125]. 
	   Individuals experiencing this transitional state between normal ageing and 
dementia are still able to live independently, but have an increased risk of developing 
dementia. MCI is classified as CDR 0 or 0.5 and furthermore subdivided into amnestic 
and non-amnestic MCI, depending on whether memory impairment is or is not involved 
in the clinical picture. Overall conversion rates to AD have been reported to range from 
27% to 49%, depending on the subtype of MCI [126]. Annual progression rates have 
varied between 6–10% in epidemiological studies and 10–15% in clinical referral settings 
[126-128].  
 
Biomarkers	  of	  AD	  
Biomarkers (or biological markers) are defined as indicators of biological processes, normal 
or pathogenic, that can be measured objectively to evaluate disease state or progression, 
guide clinical diagnosis, or monitor therapeutic interventions [129]. Potential treatment 
effects are very likely to be most if at all efficient at very early, preferably preclinical disease 
stages as much of the typical AD pathology forms years before clinical symptoms arise. The 
major aim of biomarker research is thus besides assisting a reliable clinical diagnosis of AD, 
to characterise early disease processes and put these in context to each other. 
 
Neuroimaging	  
Neuroimaging with advanced techniques such as positron emission tomography (PET), 
structural and functional magnetic resonance imaging (MRI), and single photon 
emitting computed tomography (SPECT), has gained immense importance as a tool for 
diagnosis, treatment evaluation, and research into AD during the recent decade. Several 
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breakthroughs and paradigm shifts in AD research have been based on findings of 
neuroimaging studies. 
	  
Magnetic	  resonance	  imaging	  
Magnetic resonance (MR) brain imaging is widely used in assisting the clinical diagnosis 
of AD and is a well-established tool in AD research. Good availability, the non-invasive 
nature, and relatively low costs are important advantages of this technique. The actual 
MRI technique embraces a variety of different applications, which can roughly be 
divided into structural (volumetric, diffusion-weighted, diffusion tensor (DTI)), 
functional (perfusion, blood oxygenation level-dependent (BOLD) functional MRI 
(fMRI), arterial spin labelling (ASL)), and spectroscopic (MRS) applications. Structural 
MRI, especially measures of volumes and cortical thickness, has so far been the most-
used application of this technique in AD, based on the fact that atrophy as assessed by 
MRI and neuronal loss as well as NFT pathology are highly correlated [130, 131].  
 
Figure	  5.	  Automated	  segmentation	  results	  for	  longitudinal	  structural	  MRI	  scans	  in	  an	  MCI	  patient	  
progressing	  to	  AD	  (Courtesy	  Dr	  Spulberg,	  Karolinska	  Institutet).	  
	  
Atrophy of the medial temporal lobe, more specifically the hippocampus and the 
entorhinal cortex, has consistently been shown to distinguish between AD patients and 
healthy controls with high sensitivity and it progresses more rapidly in AD patients and 
in individuals at risk of sAD [132-136]. Manual outlining of these regions is time-
consuming, and this is why several automated procedures have been developed and 
refined. Figure 5 shows an example for results from an automated segmentation as 
implemented in the FreeSurfer software package (http://surfer.nmr.mgh.harvard.edu). 
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Structural MRI studies in eoFAD mutation carriers are rare, some have been suggesting 
that atrophic changes occur closer to the expected age of AD onset than, for example, a 
decrease in glucose metabolism [137, 138]. Of interest is a recent study that revealed 
increased entorhinal cortical thickness in PSEN1 mutation carriers about 10 years prior 
to expected disease onset, suggesting inflammatory processes underlying the hypertrophy 
[139]. 
 An interesting novel approach is the combination of structural or fMRI with 
amyloid imaging by means of PIB PET (see "PIB in AD: Amyloid") to assess the 
disruption of neuronal networks in relation to regional fibrillar amyloid burden [140, 
141]. 
 
Positron	  emission	  tomography	  
In the early 1950s, the first experimental positron imaging devices were developed to 
improve imaging of brain tumours and other brain disorders [142]. Gradual 
improvement of apparatus and technique finally led to today's positron emission 
tomography (PET), an unparalleled method providing measurements of functional and 
pathological processes in vivo. A PET examination requires highly specialised equipment 
and personnel and is therefore often put in competition with less costly and better 
accessible functional imaging methods, such as fMRI or SPECT. Yet PET can not only 
image (visualise) a broad variety of functional processes but also quantitatively measure 
them, a unique feature that is not shared by other methods.   
	  
Principles	  of	  PET	  
PET is a tomographic modality (tomography: "A method of producing a three-dimensional 
image of the internal structures of a solid object (such as the human body [...}) by the 
observation and recording of the differences in the effects on the passage of waves of energy 
impinging on those structures." [143]) for imaging the spatial and temporal distribution of 
radioactive tracers (ligands, biological indicators) at a molecular level. These tracers are 
labelled with positron emitting radionuclides (isotopes) with short half‐life (Table 2), 
which are produced in a particle accelerator called a cyclotron. 
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Isotope	   Half-­‐life	  (min)	   Characteristics	  
15O	   2.05	   Used	  in	  blood	  flow/activation	  studies	  
11C	   20.4	   Replaces	  natural	  carbon	  in	  molecules	  (many	  application	  areas)	  	  
68Ga	   68.3	   Used	  for	  transmission	  scan	  (tissue	  attenuation	  correction)	  
18F	   110	   Long	  half-­‐life	  (better	  availability	  for	  sites	  without	  cyclotron)	  
	  
Table	  2.	  Isotopes	  typically	  used	  in	  brain	  PET.	  
	  
To create a tracer, a radionuclide is chemically attached to a specific tracer molecule, 
which is administered systemically and distributed by the blood to its specific target. 
There, the tracer undergoes β‐decay, emitting positrons that are annihilated by electrons, 
in turn producing two 511 keV photons (γ rays) at 180° to each other. Scintillation 
detectors (crystals) detect the coincidental photon impacts and the location of the decay 
can be reconstructed along the line of response (LOR) (Figure 6). 
 
 
	  
Figure	  6.	  Basic	  principles	  of	  PET.	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Multi-­‐tracer	  PET	  approach	  
 
PET is a molecular imaging technique, providing in vivo insights in physiological and 
pathological processes at a molecular level. Multi-tracer PET, the combination of different 
tracers allows the observation of, for example, disease-specific changes in several systems by 
gathering complementary information on these processes. As for AD, many aspects of its 
pathology are known or suggested to start early and show dynamic progress. PET using 
multiple tracers can detect many of these changes in vivo and describe them from different 
angles. PET tracers are radiolabelled molecules that can have hugely varying binding 
capacities and sites and thus explore an equal amount of potential targets. The choice of a 
respective radionuclide (Table 2) is based on specific needs, shorter half-lives enable 
multiple consecutive studies, whereas longer half-lives can be of use if, for example, slower 
metabolic processes are to be studied. Of great benefit is the use of multi-tracer PET in the 
evaluation of potential treatment efficacy. It enables monitoring of different effects a 
treatment has on molecular mechanisms in reduced sample sizes, as examples from our 
group have shown where, for example, the effects of AChEI treatment on nicotinic binding 
site density, AChE activity, glucose metabolism, and blood flow were measured [144-147]. 
 In this work, a multi-tracer PET approach was employed combining tracers for the 
study of glucose metabolism, monoaminoxidase-B activity as a marker for astrocyte 
activation, and a tracer for fibrillar amyloid pathology (Figure 7). These tracers and the 
study aims are described later. 
 
 
Figure	  7.	  Multi-­‐tracer	  approach	  employed	  in	  this	  work.	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Some general aspects should be considered here: 
 Comparison between different studies can be complicated by variations in 
 standards of processing, modelling, and analysis of PET data. 
 Effects of several kinetic aspects on tracer delivery, distribution, and binding (e.g. 
blood flow component, atrophy in AD) must be taken in account. 
 For some tracers, the target is well characterised but not the actual binding site and 
its features. 
 
PET	  scanner	  
Early positron imaging devices had scintillation detectors gathered in two arrays opposite 
to each other. Modern PET scanners feature hexagonal, octagonal or fully circular 
detector arrays with commonly 12-15 cm field of view (FOV) and resolutions of 4-5 mm 
full-width half-maximum (FWHM) [148]. A dedicated high-resolution research 
tomograph (HRRT) can achieve up to <2 mm FWHM in resolution [148, 149]. 
Nowadays, many PET scanners are combined with structural imaging devices such as X-
ray computed tomography (CT), and recently also PET/MRI combinations have become 
commercially available. Last generation PET scanners also feature very high timing 
resolution that enables time-of-flight (TOF) reconstruction. TOF allows correction for 
tiny timely differences in the detection of each annihilation photon along the LOR [150]. 
 
Data	  acquisition	  and	  processing	  
PET examinations are either performed as static scans or as dynamic time series with 
several time frames. Dynamic PET imaging involves a sequence of contiguous 
acquisitions upon tracer injection, each of which can last between 10 s and 20 min, 
depending on the used tracer. Upon acquisition, the radiation data from the camera is 
corrected for tissue attenuation and scatter, reconstructed, and finally corrected for 
motion. 
	  
Data	  visualisation	  and	  modelling	  	  
The quantitative image resulting from data processing displays radiation values for each 
voxel (Bq/voxel) in a scanned volume. The most basic analysis is a visual evaluation 
either of the individual time frames or of a summation image of several (usually late) 
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frames. In a next step, ratios can be calculated by measuring tracer activity in a defined 
region or volume of interest (ROI/VOI) and dividing other ROIs/VOIs or global activity 
by the values obtained from the reference region. The Standardized Uptake Value (SUV) 
is calculated by dividing each voxel's radioactivity at a certain time point by the injected 
dose (Bq) and the person's body weight (kg) [151]. Ratios and SUVs are commonly used 
for simple measures of biodistribution or characterisation of diseases. 
 More complex mathematical models have to be applied for the calculation of 
certain physiological parameters. To relate local tracer activity to biochemical processes, 
tracer transfer between different compartments has to be modelled. These compartments 
represent either anatomical spaces that can not be visualised by scanner resolution or 
different biochemical states of the tracer in the same site [152]. These models require an 
input function, a measure of the arterial tracer concentration that is available to the brain. 
Arterial blood samples are ideally used for calculating the input function but cause 
significant inconvenience for the proband. This is why in many cases, especially for 2-
[18F]-fluoro-2‐deoxy‐D‐glucose (FDG) PET scans, "arterialised" venous blood from a 
heated hand vein is used [153]. Other possibilities for creating an input function are the 
definition and application of a reference region or the direct measurement of arterial 
tracer activity on high-resolution PET images [152]. 
 
Quantitative	  regional	  analysis	  
Accurate anatomical PET data analysis is aggravated by the rather poor spatial resolution 
of standard PET scanners (4-5 mm FWHM), which exceeds e.g. average brain cortical 
thickness [154]. Manual outlining of cortical ROIs/VOIs (Figure 8A) directly on the 
processed PET images is thus a fairly crude method that may be guided by signal 
"hotspots" rather than by actual anatomy and leads to over-/underestimation of detailed 
regional data. Better anatomical accuracy is achieved by placement of ROIs/VOIs on the 
individual's coregistered MRI scan. A confounding factor is hereby the "spill-over" of 
tracer signal from other tissue compartments, such as white matter or CSF, into the grey 
matter, called partial volume effect [155]. Especially in disorders like AD, where the 
brain is subject to massive atrophy, outlining ROIs/VOIs without partial volume 
correction often leads to an underestimation of regional signal due to partial volume 
effects [156]. 
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Figure	  8.	  Different	  methods	  for	  PET	  data	  analysis.	  (A)	  Manual	  outlining	  of	  ROIs	  directly	  on	  slices	  of	  PET	  
images.	  (B)	  Predefined	  atlas	  (exemplified	  by	  a	  three-­‐dimensional	  rendering	  of	  the	  "Hammersmith"	  atlas	  
based	  on	  30	  segmented	  MRI	  scans	  [157]),	  which	  is	  applied	  onto	  a	  PET	  scan	  in	  the	  same	  space.	  (C)	  Colour	  
coded	  SPM	  T	  map	  showing	  results	  from	  a	  group	  comparison	  projected	  on	  an	  MRI	  template.	  
	  
	  
The probably most accurate method for regional analysis constitutes the application of a 
predefined anatomical atlas (Figure 8B) after spatial normalisation of either the PET scan 
or the atlas guided by the corresponding MRI scan. 
 Voxel-based analysis based on the general linear model as provided by the free 
software package SPM (Statistical Parametric Mapping, Wellcome Institute, London, 
UK), is particularly useful when PET data from groups are compared to each other. In 
short, individual PET scans are spatially normalised to a template, followed by voxel-by-
voxel (mass-univariate) comparison between the means of the two groups. The resultant 
statistics are then presented in a statistical parametric map (Figure 8C). 
 
PET	  in	  AD	  
The first PET studies in AD patients date back to the early 1980s. One of the earliest 
used 15O to study cerebral oxygen supply [158], following studies used 18F-FDG PET to 
assess glucose metabolism [159-161]. Since then, many more compounds have come 
along and countless PET scans have been performed in the study of AD. Table 4 
provides an overview of PET tracers that have been or are in use in AD research. 
 
Blood	  flow	  
Most nuclear imaging studies assessing cerebral perfusion or blood flow in AD have made 
use of SPECT, showing decreased perfusion in brain regions that typically also display 
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impaired glucose metabolism (see “Glucose metabolism”), such as posterior cingulate and 
parietotemporal cortical regions [162, 163]. Some studies have used PET with 15O-H2O to 
evaluate perfusion, a tracer with a half-life of merely 2 min, which enables acquisition of 
multiple data sets over a brief period but requires on-site production and fast handling 
[164, 165]. Separate PET examinations to study cerebral blood flow might though be 
rendered unnecessary by making use of the early time frames of e.g. FDG and/or PIB PET 
scans, reflecting the tracer delivery phase by blood, as a measure of perfusion [166-168]. 
 
Glucose	  metabolism	  
Glucose utilisation in tissue can be measured by 2-[18F]-fluoro-2‐deoxy‐D‐glucose 
(FDG) PET. FDG, a radiolabelled glucose analogue, is actively transported into cells by 
a group of transport proteins (GLUT) and phosphorylated by hexokinase to FDG-6-PO4, 
which in contrast to phosphorylated natural glucose can not be further metabolised via 
glycolysis [169]. It is therefore essentially trapped in cells at least for the duration of an 
average PET scan of 45 to 90 min. 
 FDG PET has been used to evaluate deterioration in the AD brain for almost 30 
years [159-161] and is certainly the best-evaluated PET tracer in AD research, 
increasingly also used in the clinical diagnosis of AD. Against a background of global 
hypometabolism, numerous studies have reported a specific decrease in glucose 
metabolism in the parietotemporal association and angular and posterior cingulate 
cortices, as well as the medial temporal lobe including structures such as the 
hippocampus and entorhinal cortex, whereas regions like the cerebellum, pons, striatum, 
sensorymotor and primary visual cortices remain spared in sAD patients [170-172]. This 
pattern can vary with age of disease onset and disease severity. One study revealed more 
severe hypometabolism in parietal, frontal, and several subcortical areas, while in another 
study greater impairment in parietal and posterior cingulate cortices and precuneus in 
eoAD when compared with loAD was reported [173, 174]. The diagnostic accuracy of 
FDG PET as regards a definite AD diagnosis has been shown to be over 90% in terms of 
sensitivity in pathologically confirmed AD, exceeding previous clinical diagnostic 
accuracy significantly [175, 176]. 
 The decrease in cerebral glucose metabolism (CMRglc) is closely related to 
cognitive decline [177-179] and hence has consistently been shown to be a reliable 
predictor for the progression from healthy ageing to MCI and from MCI to AD. 
  23 
Hypometabolism mainly in the posterior cingulate cortex and medial temporal lobe, 
more precisely the hippocampus, but also in the parietotemporal cortex has figured as a 
robust measure of disease progression [180-185]. Furthermore, CMRglc reductions in 
the angular, left mid-temporal, and left middle frontal gyri have been shown to be 
associated with faster cognitive decline among cognitively healthy individuals [186]. 
Likewise, hypometabolism, albeit mild, has been observed in the same regions as in 
clinically affected AD patients in non-demented individuals carrying at least one ApoE ε4 
allele compared with non-carriers and has been shown to be progressive and to correlate 
with cognitive performance in these individuals [187-190]. 
 A few studies have assessed the pattern of hypometabolism in pre-symptomatic 
carriers of eoFAD mutations, all of which demonstrated regional abnormalities prior to 
the development of cognitive impairment. The results of these studies varied somewhat, 
very likely due to the fact that they each embraced different eoFAD mutations at 
different time spans from their expected age of disease onset. In summary, a decrease was, 
often accompanied by global CMRglc impairment, most commonly observed in parietal, 
parietotemporal, temporal, posterior cingulate, and entorhinal cortical regions, but also 
in subcortical structures such as the hippocampus and the thalamus [137, 138, 191-194].  
 An interesting connection to mitochondrial dysfunction was established by the 
finding of declining glucose metabolism in brain regions typically affected in AD in 
individuals with a maternal, rather than paternal, family history of AD [195, 196]. This 
concept has further been validated by the observed correlation between post-mortem 
mitochondrial dysfunction and in vivo FDG PET measures in the posterior cingulate 
cortex [197, 198]. 
 FDG PET has also been proved to be a valuable outcome measure in treatment 
studies [144, 147], permitting a substantial decrease in the required sample size in 
treatment trials [179, 199]. 
 The FDG PET signal is commonly referred to as a surrogate marker of neuronal or 
synaptic integrity. It is still an unresolved issue to what extent astrocytic glycolysis 
accounts for that signal; this knowledge should contribute significantly to the 
understanding of measures of glucose metabolism by FDG PET [72, 73]. 
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Neurotransmitters	  
In a complex disorder such as AD, all neurotransmitter systems are affected. In particular 
the acetylcholine system is impaired as a consequence of neuronal loss in cholinergic brain 
nuclei such as the nucleus basalis Meynert and decreased levels of acetylcholine (ACh) and 
acetylcholinesterase and acetyltransferase activity [200]. PET studies using tracers for 
AChE activity such as 11C-MP4A and 11C-PMP have shown decreased binding in AD and 
MCI patients when compared to normal controls [201]. Different tracers are under 
development for different subtypes of ACh (nicotinic and muscarinic) receptors, Table 4 
provides an overview of these compounds. 
The PET tracer portfolio offers the possibility to study dopamin synthesis, storage, 
receptor binding, reuptake, or vesicular transporter of dopamine. In AD, striatal D1 
receptors have been shown to be reduced in comparison with controls; D2 receptor 
binding potential, however, was decreased in the hippocampus and in temporal cortical 
regions [202]. 
 Cognitive function has recently been associated with the serotonin transporter 
(SERT) [203], and a significant reduction in 5-HT2A receptor binding has furthermore 
been revealed in early MCI patients. These levels remained stable on a lower level than 
those in controls over a two-year follow-up, even in patients who converted to AD [204]. 
 
β-­‐Amyloid	  
With Aβ being a central component of AD pathogenesis, the rise of PET imaging ligands 
that could visualise Aβ pathology was a minor revolution. The first amyloid tracer to come 
to use in 2002 [205], N‐methyl-[11C]-2‐(4'‐methylaminophenyl)‐6‐hydroxy‐
benzothiazole, called Pittsburgh Compound B (PIB), a thioflavin T derivate, is still the 
most widely used. PIB crosses the blood-brain barrier and binds with high nanomolar 
affinity to insoluble fibrillar aggregates of Aβ [206], predominantly to fibrillar neuritic 
plaques but also to vascular Aβ pathology in form of cerebrovascular amyloidogenic 
angiopathy (CAA) [207, 208]. It has also been shown to correlate well with measures of 
insoluble Aβ and 3H-PIB binding in post-mortem brain tissue, amongst others from the 
first-ever patient to be scanned with PIB in vivo [207, 209, 210]. 
 The first PIB PET study in humans, carried out in Uppsala in patients from the 
Karolinska University Hospital Huddinge and in collaboration with the Pittsburgh 
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Figure	  9.	  Representative	  11C-­‐PIB	  PET	  scans	  of	  age-­‐matched	  individuals. 
 
group, found that PIB retention was significantly higher in the frontal and 
temporoparietal association cortices as well as in the striatum in AD patients compared 
with healthy controls [211]. PIB retention was similar in patients and controls in brain 
regions known to be relatively unaffected by amyloid deposition, such as the pons, the 
cerebellum and subcortical white matter. This differentiation could be replicated by 
several subsequent studies in AD patients and healthy individuals [212-214]. PIB 
retention seems to remain stable over time once AD is diagnosed [215, 216], a pattern 
well reflected by the poor correlation between FDG PET measures of decreasing glucose 
metabolism and PIB retention, although few regional correlations have been reported 
[216-219]. 
 The pattern of PIB retention in MCI can be described as quite dichotomous. 
Those MCI patients who eventually will convert to AD show usually higher and 
temporally increasing PIB retention than those who will most probably remain stable or 
return to a more normal cognitive state [220]. Interestingly, increased PIB retention has 
also been demonstrated in a substantial amount of healthy elderly [214]. It has been 
argued that these individuals might be at an increased risk of developing cognitive 
decline. 
 With low CSF levels of Aβ being supposed to represent high Aβ brain deposition, 
a clear inverse relationship to PIB retention has been shown [219, 221]. However, several 
  26 
cases have been described with abnormally low CSF Aβ levels and no elevated PIB 
detected by PIB PET [222, 223]. 
Genetic risk factors and causes of AD have furthermore been reported to 
predispose for PIB retention. Both cognitively normal elderly and AD patients carrying 
ApoE ε4 alleles revealed gene dosage dependent higher PIB retention levels than non-
carriers [224, 225]. Studies in eoFAD mutation carriers demonstrated particularly high 
PIB uptake in the striatum, already at young pre‐symptomatic and at symptomatic 
disease stages where also high cortical levels were observed [226-228]. 
The short half-life of 11C renders the use of PIB distant from a cyclotron 
impossible. This is why several 18F-labelled compounds have been developed (Table 4). 
The first, 18F-FDDNP was shown to bind to both fibrillar Aβ and tau pathology and to 
differ somewhat from PIB with regard to the dynamic range of retention [229, 230]. 
Recently, fluorinated tracers such as 18F-Florbetaben [231] 18F-Flutemetamol (also called F-
PIB, similar structure) [232] 18F-Florbetapir (also called 18F-AV-45) [233] have 
demonstrated promising binding characteristic and diagnostic properties with regard to 
AD. The US Food and Drug Administration (FDA) has recently evaluated 18F-AV-45 but 
not yet approved. Issues of clinical application in terms of AD assessment will have to be 
resolved before amyloid ligands can become part of a diagnostic routine. 
 
Neuroinflammation	  
Microglia	  
PET ligands for in vivo visualisation of microglial activation make use of their high 
affinity to the peripheral benzodiazepine-binding site (PBBS/PBR), also called 
translocator protein (TSPO), a receptor located in the outer membrane of mitochondria. 
Its upregulation within the CNS has been shown to reflect neuroinflammatory processes, 
mainly due to the activation of microglia [234, 235]. The most used PET ligand to study 
microglial activation is the 11C-labelled isoquinoline (R)-PK11195 (1-[2-chlorophenyl]-
N-methyl-N-[1-methyl-propyl]-3-isoquinoline carboxamide) (PK11195), a specific 
ligand for TSPO. An early PK11195 PET study that did not show any difference 
between AD patients and a group of controls suffered from several methodological issues 
[236]. Subsequent PET studies used the aforementioned more active R-enantiomer of 
PK11195 and applied different and more advanced quantification approaches to 
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improve tracer evaluation [237, 238]. One of these found increased binding levels in the 
entorhinal, temporoparietal, and cingulate cortex in a group of AD patients and one 
subject with mild cognitive impairment (MCI) in comparison with normal individuals 
[239]. Several studies have combined PK11195 PET imaging with PET examination of 
fibrillar amyloid with PIB and dementia assessments to explore the relationship of 
microglial activation with underlying pathology in AD and MCI. One reported 
increased PK11195 binding in AD patients in comparison with normal controls in 
parietotemporal regions and a negative correlation with PIB retention levels in the 
posterior cingulate, which also showed lowest glucose metabolism as measured by 18F-
FDG PET [240]. Another study found increased PK11195 cortical binding and a two-
fold elevated PIB retention in the same cortical areas of AD subjects when compared to 
healthy controls [241]. A study in 14 MCI patients showed that half of them had 
increased cortical PIB retention while only five had increased PK11195 levels, and no 
regional correlation between the tracers was found [242]. No difference in PK11195 
binding between mild to moderate AD patients, MCI patients and control subjects and 
no regional correlation with PIB retention were found in once another study claiming 
that microglial activation might be associated with later stages of AD alone or that 
PK11195 might be too insensitive to detect microglial activation at the examined disease 
stages [243]. This is, however, in disagreement with a study showing increases in 
microglial activation even during healthy aging [244]. 
 Even if PK11195 is still considered the "gold standard", the results of PET studies 
in AD and MCI have been rather discordant, especially in earlier disease stages. New 
tracers such as N-(2,5 dimethoxybenzyl)-N-(4-fluoro-2-phenoxyphenyl) acetamide 
(DAA1106) have higher binding affinity to TSPO and binding characteristics superior to 
PK11195. One study has so far been conducted in AD showing significantly higher 
binding in cortical regions, as well as in the striatum and the cerebellum of AD patients 
compared with controls [245]. Another TSPO ligand, 11C-vinpocetine, has also been 
suggested as a potential marker for microgliosis. No difference between AD patients and 
age matched control subjects was observed, however, disease and age specific changes 
could successfully been demonstrated [246]. Interestingly, two different TSPO binding 
sites with different affinities have recently been identified, which might explain the 
variation in the PET studies using TSPO tracers [247]. 
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Category	   PET	  tracer	   Measures	  
Functional	   18F-­‐FDG	   Glucose	  metabolism	  
	   15O-­‐H2O	   Blood	  flow	  
Acetylcholine	  
transmitter	  
system	  
11C-­‐PMP	   AChE	  activity	  
11C-­‐MP4A	   AChE	  activity	  
11C-­‐Nicotine	   Nicotinic	  ACh	  receptor	  levels	  
18F-­‐Fluoro-­‐A-­‐85380	   Nicotinic	  ACh	  receptor	  levels	  
11C-­‐NMPB	   Muscarinic	  ACh	  receptor	  levels	  
11C-­‐Benztropine	   Muscarinic	  ACh	  receptor	  levels	  
11C	  -­‐CHIBA-­‐1001	   α7	  nicotinic	  receptor	  levels	  
Dopamine	  
transmitter	  
system	  
18F-­‐Fluordopa	   Dopamine	  synthesis	  and	  vesicular	  storage	  
11C-­‐SCH-­‐23390	   D1	  receptor	  levels	  
11C-­‐Raclopride	   D2	  receptor	  levels	  
Serotonine	  
transmitter	  
system	  
11C-­‐MPPF	   5-­‐HT1A	  receptor	  levels	  
18F-­‐Altanserin	  	   5-­‐HT2A	  receptor	  levels	  
11C-­‐SB207145	   5-­‐HT4	  
	   11C-­‐DASB	   SERT	  
Pathology	   11C-­‐PIB	   Fibrillar	  amyloid	  
	   18F-­‐Flumetamol	   Fibrillar	  amyloid	  
	   18F-­‐Florbetapir	  (AV-­‐45)	   Fibrillar	  amyloid	  
	   18F-­‐FDDNP	   Fibrillar	  amyloid	  /	  tau	  
	   11C-­‐SB-­‐13	   Fibrillar	  amyloid	  
	   11C-­‐BF-­‐227	   Fibrillar	  amyloid	  
	   18F-­‐THK523	   Tau	  (experimental)	  
Inflammation	   11C-­‐(R)-­‐PK11195	   Translocator	  protein	  system	  (TSPO),	  Microglia	  
11C-­‐DAA1106	   TSPO,	  Microglia	  
11C-­‐Vinpocetine	   TSPO,	  Microglia	  
11C-­‐L-­‐Deprenyl	  (DED)	   Monoaminoxidase	  B	  (MAO	  B),	  Astrocytes	  
	  
Table	  4.	  PET	  tracers	  (trivial	  names)	  used	  in	  AD	  research.	  
  
Astrocytes	  
11C-L‐deuterium-deprenyl (DED) binds to monoamine oxidase B (MAO-B), an enzyme 
abundant predominantly in the mitochondria of astrocytes and in serotonergic neurons 
in the human brain [248-250]. Enhanced MAO-B activity has been related to astrocytic 
activity, in post-mortem tissue mostly associated with Aβ plaque pathology [251-253]. 
DED PET has been used in the study of amyotrophic lateral sclerosis [47] and 
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Creutzfeldt‐Jakob [48] disease, amongst others, demonstrating increased DED binding 
in the brains of patients in comparison with controls. Very recently, the first study 
involving AD patients and healthy controls has been published. This study revealed no 
difference in DED binding between a group of AD patients and healthy controls, 
however, after applying a binding over tracer distribution ratio that was considered to 
correct for differences in blood flow between patients and controls, the AD patients 
showed higher values of this ratio in frontal, parietal, and temporal lobes [254]. Pure 
DED binding did not correlate with PIB retention, although ratio values correlated with 
PIB retention in the occipital cortex (see also "Results & Conclusion"). 
 
Tau	  
So far, no study has been published concerning the use of a PET tracer specific for tau 
pathology in humans. There are though several candidate ligands [255], of which at least 
one, 18F-THK523, has been studied in transgenic mice, with promising results, and it is 
currently being studied in AD patients [256]. 
	  
Cerebrospinal	  fluid	  biomarkers	  
Cerebrospinal fluid (CSF) is a bodily fluid present in the ventricular system within and 
around the brain and in the central canal of the spinal cord. It is accessed and acquired by 
lumbar puncture, a relatively safe and cost-effective procedure that can be carried out 
without the need of advanced technical apparatus [257]. CSF biomarkers are believed to 
reflect molecular and metabolic changes in the extracellular and interstitial environment of 
the brain given the almost unrestricted flow of molecules towards the CSF [258]. 
 CSF biomarkers for AD should ideally depict typical AD pathology. Among the 
large collection of candidates, the best established and most widely used are thus measures 
of Aβ1-42, total tau (t-tau) and phosphorylated (at threonine 181) tau (p-tau). Levels of Aβ1-
42 are commonly decreased in AD, likely due to its deposition in plaques in the brain [259, 
260], while levels of t- and p-tau are significantly elevated. T-tau thereby possibly reflects 
the amount of neuronal degeneration [261-263], while p-tau rather correlates with 
neurofibrillary tangle burden [258, 264]. 
 The combination of the three biomarkers, rather than one alone, has been proven 
to distinguish AD from cognitively healthy individuals with high sensitivity (generally 
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~90%) in numerous studies [223, 265-267]. Most longitudinal studies in AD patients 
have reported rather stable levels of Aβ1-42 and tau over time, although some showed fairly 
conflicting results [268-272]. Highly consistent, however, were results from the many 
studies evaluating how well the CSF biomarker troika predicts conversion from MCI to 
AD, reaching sensitivity values of up to 95% [265, 273-275]. Interestingly, only changes 
in CSF Aβ1-42, or t-tau or p-tau/Aβ1-42 ratio, not tau alone, predicted cognitive decline or 
eventual progression to AD in cognitively healthy individuals [276-279]. 
 Studies in carriers of different PSEN1 eoFAD mutations showed that pre-
symptomatic mutation carriers had either decreased CSF Aβ1-42 levels or Aβ1-42/40 ratios or 
showed that Aβ1-42 levels correlate with time to disease onset [280-282]. CSF levels of tau 
were either elevated at pre-symptomatic stages or at later symptomatic stages, correlating 
then with disease severity [280, 282]. One study furthermore studied Aβ species patterns 
in mostly pre-symptomatic carriers of a PSEN1 mutation and sAD patients and found that 
levels of Aβ1-42 and Aβ1-16 were similarly low in eoFAD and sAD, while the mutation 
carriers had very low levels of Aβ1-37, Aβ1-38, Aβ1-39, suggesting modulation of the γ-secretase 
cleavage site by the PSEN1 mutation [283]. Another study followed a very young pre-
symptomatic APP mutation carrier longitudinally, reporting changes in both Aβ1-42 and tau 
CSF levels whereof levels of p-tau changed most over the 4.5 y follow-up period [284]. 
 With three profoundly established core biomarkers and many candidates in the 
pipeline, CSF measures have shown encouraging results in numerous studies. However, it 
is important to consider that significant intercenter and interlaboratory variations have 
occurred in large multicenter studies [285, 286]. This is why great efforts are now 
undertaken to standardise operation procedures and increase the accuracy of measurements 
at different sites [287, 288]. 
 
Revision	  of	  the	  diagnostic	  criteria	  for	  AD	  
Based on the above-mentioned findings, Dubois and colleagues drafted in 2007 (on behalf 
of an international working group) new research criteria for the diagnosis of AD that were 
no longer based on exclusionary conditions but characterised by phenotypes [289]. The 
core innovation was based on the extended use of biomarkers, which had been subject to 
extensive research during previous years. The revised diagnosis of probable AD thus 
demanded the presence of episodic memory impairment together with so-called supportive 
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features such as the presence of medial temporal lobe atrophy assessed by MRI, abnormal 
concentrations of typical markers in CSF, or pathological patterns on functional 
neuroimaging by means of PET. A series of exclusion criteria was also specified. The 
revised criteria for definite AD included either the combination of clinical and 
histopathological or clinical and genetic evidence. 
 Two recent reports have evaluated the accuracy of these revised diagnostic criteria. 
In a retrospective study in 243 subjects with post-mortem-confirmed diagnosis, 68% 
sensitivity and 93% specificity were achieved when memory and CSF data with exclusion 
criteria were applied, and a specificity of 100% was reached when supportive features were 
included [290]. In another study the records of 150 patients were re-evaluated [291]. Here, 
55% of all patients previously diagnosed with AD, met the revised diagnostic criteria for 
probable AD. Among a group of non-demented subjects, 7.3% were diagnosed as having 
AD. Of note is that none of the subjects included in the two studies had undergone all 
recommended examinations. 
 In 2009, the NIA established three international working groups to formulate 
diagnostic criteria that would, similar to the approach Dubois et al. followed, incorporate 
all scientific advances made since the introduction of the original NINCDS-ADRDA 
criteria [292]. The three groups were to focus on the asymptomatic, preclinical phase, the 
symptomatic pre-dementia phase, and the dementia phase of AD, respectively. The new 
criteria for each of these phases were recently published in Alzheimer's & Dementia, the 
organ of the Alzheimer's Association [293-295]; they are summarised in Table 5. 
How well these new criteria will work in clinical practice is yet to be explored.  
Although there is an undisputed use in including well-established biomarkers of AD in the 
diagnostic process, not all patients will have the infrastructural or financial possibilities to 
undergo all or even some of the suggested examinations. 
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Table	  5.	  Revised	  diagnostic	  criteria	  for	  AD	  (based	  on	  [293-­‐295]).	  
	  
 
	  
	  
	  
Diagnostic	  category	   Subtle	  cognitive	  
changes	  
Biomarker	  
probability	  of	  AD	  
aetiology	  
Aβ 	  (PET	  or	  CSF)	   Neuronal	  injury	  (CSF	  tau,	  
FDG-­‐PET,	  structural	  MRI)	  
Preclinical	  stage	  1	   Negative	   	   Positive	   Negative	  
Preclinical	  stage	  2	   Negative	   	   Positive	   Positive	  
Preclinical	  stage	  3	   Positive	   	   Positive	   Positive	  
MCI–core	  clinical	  
criteria	  
	   Uninformative	   Conflicting/	  
indeterminate/	  
untested	  
Conflicting/	  
indeterminate/	  
untested	  
MCI	  due	  to	  AD—
intermediate	  
likelihood	  
	   Intermediate	   Positive	  
Untested	  
Untested	  
Positive	  
MCI	  due	  to	  AD—
high	  likelihood	  
	   Highest	   Positive	   Positive	  
MCI—unlikely	  due	  
to	  AD	  
	   Lowest	   Negative	   Negative	  
Probable	  AD	  
dementia	  
Based	  on	  clinical	  
criteria	  
	   Uninformative	   Unavailable,	  conflicting,	  or	  
indeterminate	  
Unavailable,	  conflicting,	  or	  
indeterminate	  
With	  three	  levels	  of	  
evidence	  of	  AD	  
pathophysiological	  
process	  
	   Intermediate	   Unavailable	  or	  
indeterminate	  
Positive	  
Intermediate	   Positive	   Unavailable	  or	  
indeterminate	  
High	   Positive	   Positive	  
Possible	  AD	  
dementia	  (atypical	  
clinical	  
presentation)	  
Based	  on	  clinical	  
criteria	  
	   Uninformative	   Unavailable,	  conflicting,	  or	  
indeterminate	  
Unavailable,	  conflicting,	  or	  
indeterminate	  
With	  evidence	  of	  
AD	  
pathophysiological	  
process	  
	   High	  but	  does	  not	  
rule	  out	  second	  
aetiology	  
Positive	   Positive	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Time	  course	  and	  interrelationship	  of	  biomarkers	  
The complex interplay of pathological processes underlying AD has been explored in 
multitudinous studies employing in vivo biomarkers, some of which are described above. 
Many of these studies have been conducted in different settings, with diverging patient 
characteristics and greatly varying methodology, which poses complications in comparing 
their results. As a general conclusion, however, it can be stated that the combination of 
different biomarkers not only improves the understanding of disease mechanisms but will 
also be necessary to eventually arrive at reliable clinical diagnosis. It is, however, not 
necessarily decisive to combine all available biomarkers to achieve the highest classification 
rates but rather to know at which stage of disease development a certain combination of 
biomarkers might be most useful. 
 
	  
Figure	  10.	  Hypothetical	  time	  course	  of	  AD	  biomarkers	  (based	  on	  [293,	  296-­‐299].	  
	  
	  
In an attempt to confirm findings from previous studies in standardised, large-scaled 
settings, and to set methodological standards initiatives such as the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) [300], the Australian Imaging, Biomarkers and Lifestyle 
(AIBL) study [301] for sAD, as well as the Dominant Inherited Alzheimer Network 
(DIAN) for eoFAD, have been established. ADNI has been ongoing for the past six years 
and resulted in many publications on the interrelationships of biomarkers, whereas AIBL 
and DIAN have quite recently commenced. While benefits and impact are undisputed, 
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there are limitations to these large-scaled initiatives. Both ADNI and AIBL have gathered 
groups of AD and MCI patients, as well as healthy controls aged on average well over 70 
[301, 302]. At this age, many pathological processes might already have been ongoing for 
years. The cumulated knowledge from currently available studies on AD biomarkers can be 
presented in the form of time course of the individual biomarkers. Figure 10 shows an 
adaptation of a widely accepted, albeit simplified hypothetical model of these time courses 
based on recent studies and reviews. Sigmoid rather than linear fitting has been shown to 
represent the actual time course of biomarkers more accurately [303]. 
 A modified hypothetical time course model is proposed in “Conclusions & 
Outlook” at the end of this summary. 
 
Treatment	  
AD is to date still an incurable disease. The only commercially available treatment options 
involve today symptomatic treatment with AChEI such as donepezil, rivastigmine and 
galantamine. These are licensed for mild-to-moderate AD and have been proven to 
improve cognition, function, and global clinical outcome in several controlled randomised 
trials [304, 305]. PET studies have furthermore shown beneficial effects on measures such 
as blood flow or glucose metabolism [147, 306, 307]. Except for AChEI, only memaninte, 
an N-Methyl-D-aspartic acid (NMDA)-receptor antagonist is so far licensed for treatment 
of moderate-to-severe AD. This drug has also shown to have cognitive and 
neuropsychiatric benefits in trials [308]. 
The amyloid hypothesis has been agenda setting in the development of several 
treatment strategies. Most attempts to attack potential mediators of amyloid generation 
have failed, which is one of the reasons the hypothesis has been questioned [36, 308]. But 
also most other approaches have failed so far (for a concise review of reported and ongoing 
trials, see [308]). The general understanding of AD pathology has not been sufficient to 
define a suitable treatment target, yet. 
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Aims	  
	  
The general aim of this thesis was to study eoFAD and sAD at different pre-symptomatic 
and symptomatic disease stages by using multiple PET tracers, alone or in combinations, in 
relationship to other biomarkers of AD and/or post-mortem pathology. The specific aims of 
each study were: 
 
Paper	  I	  
 To determine whether an abnormal pattern of cerebral glucose metabolism as 
measured by FDG PET could be identified in young pre-symptomatic carriers of a 
His163Tyr PSEN1 mutation on two subsequent occasions. 
 To assess the time course of glucose metabolism from pre-symptomatic to 
symptomatic stages, as well as the pattern of amyloid deposition by means of PIB 
PET retention in one of the mutation carriers. 
 
Paper	  II	  
 To examine the time course of glucose metabolism in carriers of the Met146Val 
PSEN1 mutation in relation to neuropsychological performance.  
 To explore the relationship of regional patterns of impaired glucose metabolism 
with post-mortem neuropathology. 
 
Paper	  III	  
 To investigate the particular amyloid pathology of the Arctic APP mutation in vivo 
with PIB PET in relation to CSF biomarkers, glucose metabolism, and MRI 
measures of atrophy in comparison with other eoFAD mutations and sAD. 
 
Paper	  IV	  
 To determine if there is an increase of MAO-B by means of DED PET binding as 
a measure for astrocytosis in sporadic MCI and AD patients compared to healthy 
controls and if there is a regional relationship between DED, PIB, and FDG PET 
measures. 
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Subjects	  &	  Methods	  
Ethics	  approval	  
All studies were conducted according to the Declaration of Helsinki and subsequent 
revisions and approved by the Regional Ethics Committee of Stockholm, Sweden and the 
Isotope Committee of Uppsala University, Uppsala, Sweden. 
 
Subjects	  
The participants of all four studies were recruited from the Department of Geriatric 
Medicine at the Karolinska University Hospital Huddinge. The clinical routine 
examinations generally involved physical examination, evaluation of neurological and 
psychiatric status, blood and CSF sampling, ApoE genotyping, MRI, MMSE testing, and 
detailed neuropsychological assessment. All subjects or their caregivers provided written 
informed consent to participate in the study. 
AD was clinically diagnosed according to the NINCDS-ADRDA criteria [104], often 
confirmed by biomarker results, MCI was diagnosed according to the criteria outlined by 
Petersen et al. [123] (see “Clinical diagnosis”). 
APParc
APPswe
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Neuropsychological	  assessment	  
The battery of routine neuropsychological tests that all subjects underwent included 
measures of the following cognitive domains: 
 Global cognition (MMSE [107], Full-Scale IQ (FSIQ)*) 
 Episodic memory (Rey-Auditory Verbal Learning Test (RAVLT) learning and 
recall, Rey-Osterieth Complex Figure Test recall [120]) 
 Short-term memory (Digit Span*, Corsi Span) 
 Visuospatial abilities (Block Design*, Rey-Osterieth Complex Figure Test copy) 
 Verbal abilities (Information*, Similiarities*) 
 Executive function and attention (Digit Symbol*, Trail Making Test A and B) 
(* Wechsler Adult Intelligence Scale - Revised (WAIS-R) [119]) 
	  
PET	  scanning	  
All PET examinations were performed using the following scanners: 
 GEMS 2048-15 and GEMS 4096-15 scanners (General Electric Medical Systems, 
Wisconsin, USA) featuring eight rings of bismuth germanate (BGO) crystal 
detectors which enable the acquisition of 15 contiguous image plans over a field of 
view (FOV) of 104 mm (resolution x/y/z = 5.8/5.8/6.5 mm) (Papers I and II). 
 EXACT HR+ scanner (Siemens/CTI) with 32 rings of BGO detectors, providing 
63 contiguous image planes over a FOV of 155 mm (resolution 4.4/4.4/2.46 mm) 
(Papers I, III, and IV). 
 Discovery ST PET/CT scanner (General Electric Medical Systems, Wisconsin, 
USA) with 24 BGO detector rings, providing 47 image planes over a FOV of 157 
mm (resolution 5.7/5.7/3.27 mm) (Paper III). 
 
The scans were conducted under resting conditions in a darkened room with low ambient 
noise and with the patients’ heads supported by quick-setting foam. Scanning was 
performed in three-dimensional mode, corrected for tissue attenuation, radiation scatter, 
and random coincidences and reconstructed by filtered backprojection using a Hanning 
filter. Following reconstruction, the resulting dynamic time series were corrected for 
motion. 
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Paper	  I	  
Subjects and study design 
A group of six pre-symptomatic carriers of a His163Tyr PSEN1 eoFAD mutation 
underwent FDG PET examinations on two occasions over a period of two years. The data 
was compared with data from a group of 23 healthy controls who did not carry an eoFAD 
mutation. 
 One mutation carrier was followed up longitudinally with FDG PET scans over a 
period of 12 years from baseline, following the subject from pre-symptomatic to 
symptomatic disease stages. On the last occasion, a PIB PET scan was performed and 
evaluated in comparison with data from a group of 27 sAD patients. 
 
	  
	   Pre-­‐symptomatic	  MC	  (n=6)	   HC	  (n=23)	  
Gender	  (F/M)	   -­‐/6	   9/14	  
Age	  (y)	  ±	  SD	   34.2	  ±	  7.4	   46.0	  ±	  12.2	  
Distance	  from	  expect	  age	  of	  
disease	  onset	  (y)	  
-­‐20	   	  
Education	  (y)	  ±	  SD	   11.0	  ±	  1.3	   10.8	  ±	  2.5	  
MMSE	  ±	  SD	   29.2	  ±	  1.3	   29.2	  ±	  0.8	  
APOE	  ε4+	   3	   4	  
 
Table	  6.	  Demographics	  at	  baseline.	  MC:	  PSEN1	  His163Tyr	  mutation	  carriers;	  HC:	  Healthy	  controls.	  
 
PET data acquisition and processing 
FDG PET scans were performed in all subjects at baseline and two years later. FDG 
uptake in the brain was monitored for 60 min. FDG and glucose plasma levels were 
measured in venous blood samples collected during scan time from the back of the hand. 
Modelling according to the Patlak graphical procedure [309] was used to calculate 
CMRglc, expressed in µmol/min/100g, and to create parametric images. Resulting values 
were divided by values measured in the pons to correct for inter-subject variations, since 
the pons has been reported to be amongst the least affected regions in AD [310]. 
 One MC was examined with additional FDG PET scans 10 and 12 years after 
baseline and a PIB PET scan on the last occasion. PIB retention was scanned over 60 
minutes. Mean uptake values were obtained from a 40-60 min summation image and 
further transformed into SUVs. The pons was used as a reference region (instead of the 
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cerebellar cortex) to create SUVR ratios, as cerebellar presence of amyloid pathology had 
been reported previously [311]. 
 
PET data analysis 
A set of 46 regions of interest (ROIs) was manually defined using a Scanditronix 
program (IDA, Images Display and Analyses GE 1994). All ROIs were paired for the 
right and left hemispheres, except for the pons and whole brain. Cortical ROIs were 
defined in the frontal, frontal association, parietal, parietotemporal, anterior cingulate, 
posterior cingulate, sensorimotor, primary visual, and cerebellar cortices. The ROI in the 
thalamus was drawn freehand with a size of 1 cm2. At the level of the thalamus, ROIs 
encompassing the putamen and the caudate nucleus were defined. Two circular ROIs 
(1.5 cm in diameter) were defined in the pons in two slices. A ROI in the white matter 
was defined at the level of the centrum semiovale and a ROI including the whole brain at 
the level of the thalamus. VOIs were created by linking multiple ROIs in corresponding 
regions. 
 
	  
Figure	  11.	  Location	  of	  manually	  outlined	  ROIs	  (Papers	  I	  and	  II)	  
	  
Statistics 
FDG PET ROI data were compared between mutation carriers and non-carriers by 
multivariate data analysis, namely partial least squares-discriminant analysis (PLS-DA) 
[312], employing SIMCA software (Umetrics AB, Umeå, Sweden). The results of the 
PLS-DA were visualised by plotting two components of the model against each other. 
Furthermore, all variables (in this case brain regions/ROIs) included in the analysis were 
ranked and plotted according to their importance regarding the separation of mutation 
carriers and non-carriers (variable of importance, VIP).  
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Statistical parametric mapping 
Statistical parametric mapping was carried out using SPM2 (Wellcome Department of 
Cognitive Neurology, University College London) with Matlab 6.5 software (Mathworks 
Inc., Sherbon, MA). Image data were spatially normalised into the SPM2 PET template 
in the Montreal Neurological Institute (MNI) space. A mask was created that included 
only those voxels present in all scans and applied to all individual images prior to spatial 
smoothing with a Gaussian kernel at 12 mm (FWHM). Global normalisation was 
performed by proportional scaling (global value 50ml/min/100g, grey matter threshold 
0.8). Differences between groups were analysed by two-sample t-test. The contrast was 
defined to test the hypothesis that a decrease in FDG might occur in the MCs. We 
investigated hypometabolic brain areas of k>50 voxels at a height threshold of p = 0.001 
(uncorrected). For visualisation of the t score statistics (SPM T map), the accordant 
voxels were projected onto the MRI template provided by SPM2. Local maxima were 
labelled using the Anatomical Automatic Labeling (AAL) atlas [313]. 
	  
Paper	  II	  
Subjects and study design 
Four siblings, whereof two carried a Met146Val PSEN1 eoFAD mutation, underwent 
longitudinal FDG PET scanning over a period of two and four years, respectively. The 
longitudinal FDG PET data was put in relationship to neuropsychological test data and 
FDG PET data from a group of 23 healthy controls and a group of 27 sAD patients. 
 Furthermore, neuropathology was assessed post-mortem in the brains of the 
mutation carriers, compared with data from a reference group of 249 sAD patients and 
related to regional impairment of glucose metabolism on the last scan occasion before 
death. 
 
PET data acquisition, processing, and analysis 
All subjects underwent FDG PET scanning on one or several occasions. The PET 
examinations and ROI analysis of FDG PET data were performed in accordance with the 
methodology described in Paper I. MC-1 received two, MC-2 six, and NC-1 and -2 five 
consecutive FDG PET scans. The first scan of MC2, however, had to be excluded due to 
technical issues.  
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   MC-­‐1	   MC-­‐2	   NC-­‐1	   NC-­‐2	   HC	  (n=23)	   sAD	  (n=27)	  
Gender	  (F/M)	   F	   F	   F	   M	   9/14	   13/14	  
Age	  (y)	  ±	  SD	   41.5	   40.9	   36.3	   26.4	   46.0	  ±	  12.2	   66.2	  ±	  9.2	  
Distance	  from	  age	  
of	  disease	  onset	  
(y)	  
+4.5	   +1.9	   	   	   	   	  
Education	  (y)	  ±	  SD	   9	   9	   11	   11	   10.7	  ±	  2.7	   12.1	  ±	  3.4	  
Longitudinal	  FDG	  
PET	  scans	  
2	   6	   5	   5	   	   	  
MMSE	  ±	  SD	   14	   24	   30	   30	   29.0	  ±	  0.9	   22.4	  ±	  5.2	  
APOE	  ε4	   +	   +	   -­‐	   -­‐	   4	   17	  
 
Table	  7.	  Demographics	  at	  baseline.	  MC:	  Met146Val	  mutation	  carriers;	  NC:	  Mutation	  non-­‐carriers;	  HC:	  
Healthy	  controls;	  sAD:	  Sporadic	  AD	  patients.	  
 
Post-mortem tissue analysis 
Bielschowsky silver impregnation was used to stain AD neuropathology in the brains of the 
mutation carriers, which had been handled and dissected according to routine protocols for 
the Huddinge Brain Bank [314]. Neurofibrillary tangle (NFT) and neuritic plaque (NP) 
pathology was quantified throughout the cortical thickness of several brain regions using a 
stereological analysis system. 
 
Statistics 
Repeated Measures Analysis of Variance, followed by Bonferroni post-hoc testing, was used 
to test if a statistically significant time effect could be observed in the longitudinal FDG 
PET data from MC-2. Correlations of FDG PET data with neuropsychological test results 
and quantitative measures of neuropathology were performed by Spearman's Rank 
correlation. 
 
Paper	  III	  
Subjects and study design 
Two carriers of the Arctic APP (APParc) eoFAD mutation and five related non-carriers, as 
well as one carrier of the above mentioned PSEN1 His163Tyr mutation, one carrier of the 
Swedish APP (APPswe) mutation, seven sAD patients and seven healthy controls were 
examined with PIB  and FDG PET, MRI, and CSF measures of Aβ1-42, t-tau and p-tau. 
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PET data acquisition and processing 
PIB retention was scanned dynamically over 60 min resulting in 24 time frames and FDG 
uptake over 45 min resulting in 21 frames. 40-60 min PIB summation images and 30-45 
min FDG summation images were created for subsequent analysis. 
 
	   APParc-­‐1	   APParc-­‐2	   APParc	  NC	  
(n=5)	  
PSEN1-­‐1	   APPswe-­‐1	   sAD	  
(n=7)	  
HC	  
(n=7)	  
Gender	  (F/M)	   1/6	   M	   M	   3/4	   2/5	  
Age	  (y)	  ±	  SD	   56.1	  ±	  12.8	   58	   	   64.1	  ±	  
6.1	  
59.7	  ±	  
9.5	  
Education	  (y)	  
±	  SD	  
12.0	  ±	  3.4	   	   	   	   	  
Distance	  from	  
expect	  age	  of	  
disease	  onset	  
(y)	  
+3	   -­‐3	   	   +4	   -­‐1	   	   	  
MMSE	  ±	  SD	   11	   30	   28.8	  ±	  1.3	   11	   26	   24.4	  ±	  
5.7	  
24.4	  ±	  
5.7	  
APOE	  ε4+	   -­‐	   -­‐	   1	   +	   +	   5	   2	  
 
Table	  8.	  Demographics.	  NC:	  Mutation	  non-­‐carriers;	  sAD:	  Sporadic	  AD;	  HC:	  Healthy	  controls.	  Values	  for	  
all	  APParc	  family	  members	  are	  displayed	  as	  mean	  ±	  SD	  and	  age	  for	  APPswe-­‐1	  is	  not	  shown	  for	  reasons	  
of	  confidentiality. 
	  
MRI data acquisition and analysis 
All participants underwent structural T1 MRI scanning at 3T. Cortical thickness and 
hippocampal volume measurements were carried out using a processing pipeline included 
in the Freesurfer image analysis suite (http://surfer.nmr.mgh.harvard.edu). 
 
PET data analysis 
A modified version of a digital probabilistic atlas [315] was used in each individual's 
original MRI space to extract regional PIB and FDG PET data, resulting in 29 VOIs 
(Figure 12). 
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Figure	  12.	  Atlas-­‐based	  ROI	  analysis.	  1.	  Co-­‐registration	  of	  PET	  and	  MRI	  images.	  2.	  Segmentation	  of	  MRI	  
image.	   3.	   Multiplication	   of	   a	   binary	   map	   created	   from	   the	   segmented	   grey	   matter	   MRI	   with	   the	  
predefined	   atlas	   volume.	   4.	   Application	   of	   the	   resulting	   individual	   atlas	   onto	   the	   co-­‐registered	   PET	  
image	  and	  extraction	  of	  regional	  values.	  
	  
Statistics 
For group comparisons, the Mann-Whitney U Test was applied. For individual subject 
comparisons, z-scores were created for each modality based on the values from the HC. 
 
Paper	  IV	  
Subjects and study design 
Eight MCI and seven sAD patients were scanned with FDG, PIB, and DED PET. The 
MCI patients were divided into MCI PIB+ and MCI PIB- according to their levels in PIB 
retention. The DED PET data were compared with data from a group of 14 healthy 
controls. 
	  
	   HC	  (n=14)	   MCI	  PIB-­‐	  (n=3)	   MCI	  PIB+	  (n=5)	   sAD	  (n=7)	  
Gender	  (F/M)	   9/5	   1/2	   3/2	   3/4	  
Age	  (y)	  ±	  SD	   64.7	  ±	  3.6	   65.3	  ±	  6.6	   61.0	  ±	  8.3	   65.0	  ±	  6.3	  
Education	  (y)	  ±	  SD	   	   	   	   	  
MMSE	  ±	  SD	   	   27.7	  ±	  2.3	   27.4	  ±	  2.3	   24.4	  ±	  5.7	  
APOE	  ε4+	   	   1	   3	   5	  
 
Table	  9.	  Demographics.	  HC:	  Healthy	  controls;	  MCI:	  Mild	  cognitive	  impairment	  patients;	  sAD:	  Sporadic	  
AD	  patients;	  PIB	  +:	  Sum/pons	  values	  >	  1.41.	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PET examinations, processing, and analysis 
All FDG and PIB PET examinations were performed and the images processed and 
analysed as in Paper III except for that all analysis were performed in DED PET native 
space to preserve the DED scans integrity. DED PET acquisition was conducted over 60 	  
min (19 time frames). Dynamic DED uptake data was modelled between 20 to 60 min 	  
according to a modified reference Patlak approach [316], using the cerebellar grey matter 
corrected for net tracer accumulation as reference region. This modelling produced two 
measurements: Intercept (initial tracer distribution volume) and slope (binding of DED to 
MAO-B) (Figure 13). 
 
	  
Figure	  13.	  Modelling	  of	  DED	  PET	  data.	  (A)	  Time	  activity	  curve	  for	  the	  cerebellar	  reference	  region	  before	  
and	  after	  correction	  for	  specific	  tracer	  binding	  using	  the	  smallest	  fixed	  correction	  factor	  that	  would	  still	  
lead	  to	  linearisation	  in	  the	  Patlak	  plot	  (B).	  
 
Statistics 
Analysis of Variance (ANOVA) with Fisher's Least Significant Difference (LSD) post-hoc 
testing was employed to test for significant group differences. Relationships between the 
different PET tracers were tested by Pearson's correlation with and without Bonferroni 
correction for multiple comparisons. 
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Results	  &	  Discussion	   	  
Early	  thalamic	  glucose	  hypometabolism	  in	  PSEN1	  His163Tyr	  mutation	  carriers	  
The pattern of cerebral glucose hypometabolism in sAD and MCI is well described, 
commonly involving posterior cingulate, parietotemporal, and hippocampal impairment, 
with other regions being affected at different disease stages (see “PET in AD: Glucose 
metabolism”). However, only very few studies have assessed this pattern in carriers of 
eoFAD mutations. Early studies have shown focally decreased glucose metabolism in the 
parietotemporal cortex against a background of global impairment and mild cortical 
atrophy as measured with MRI in pre-symptomatic PSEN1 mutation carriers when 
compared with age-matched healthy controls [191, 192]. These subjects were on average 
examined 2-3 years prior to their expected age of onset. In a longitudinal study, glucose 
metabolism in temporal cortical regions in pre-symptomatic APPswe mutation carriers 
was assessed and it was found to be decreased in these regions several years before disease 
onset, exceeding MRI measures of atrophy [138]. More recently, another study showed 
that hypometabolism mainly in the posterior cingulate, entorhinal, inferior parietal and 
superior temporal cortices as well as in the hippocampus and the whole brain, preceding 
atrophy in pre-symptomatic carriers of PSEN1 carriers approximately 13 years before 
disease onset [137]. Finally, one study combined FDG with PIB PET examinations in 
seven pre-symptomatic and symptomatic PSEN1 and one APP mutation carriers, 
observing no consistent pattern of hypometabolism in early pre-symptomatic stages, 
while PIB retention seemed to start in the striata of these individuals [227]. 
We examined six pre-symptomatic carriers of a PSEN1 His163Tyr mutation on 
two occasions, on average 20 and 18 years before expected disease onset, respectively, in 
comparison with 23 age-matched non-carriers (Paper I). SPM analysis revealed lower 
glucose metabolism in the right thalamus of the mutation carriers, first by trend, and at 
follow-up statistically significant (baseline: n.s., follow-up: p=0.028 corrected at cluster 
level; p=0.034 corrected at voxel level) (Figure 14). PLS-DA furthermore showed 
significant separation of mutation carriers from non-carriers, reaching 83% sensitivity 
and 100% specificity at baseline and 100% sensitivity and specificity at follow-up, using 
all FDG PET ROIs as variables. The region contributing most to the separation between 
the groups was the right thalamus on both occasions, with other regions such as the left 
thalamus, right parietotemporal, right posterior cingulate, and right temporal cortex 
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ranking thereafter. The thalamus has previously been reported to be hypometabolic in 
pre-symptomatic and symptomatic eoFAD and sAD [194, 227, 317] and to show 
decreased activation in response to a memory paradigm in a large fMRI study in 
asymptomatic individuals at risk for familial AD [318]. Similar to our findings, clear 
lateralisation of hypometabolic patterns has also been observed before in early stages of 
AD, potentially reflecting neuroplastic compensatory mechanisms [171, 173]. 
 
	  
Figure	  14.	  Results	  from	  PLS-­‐DA	  and	  SPM	  analyses	  at	  baseline	  (A,	  C)	  and	  after	  two	  years	  (B,	  D)	  showing	  
separation	  of	  mutation	  carriers	  and	  non-­‐carriers	  by	  FDG	  PET	  (A,	  B)	  and	  the	  thalamus	  differing	  between	  
the	  groups.	  
	  
The thalamus is likely to be involved in early pathological changes in the development of 
AD. Thalamic connections are pivotal constituents of networks involved in memory 
processing that include brain regions such as the posterior cingulate cortex, the 
hippocampus, and cortical association areas, which commonly reveal decreased glucose 
metabolism in later disease stages [319-322]. 
Our findings suggest that impairment of glucose metabolism started in the 
thalamus of our mutation carriers. Methodological considerations when interpreting the 
data should, however, be taken into account. Analysis of regional glucose metabolism 
with FDG PET without correction for partial volume effects might be compromised in 
smaller structures, for example, by proximity to the CSF, as is the case with the thalamus. 
Since our data set was relatively small and only comprised carriers of one specific eoFAD 
mutation, general conclusions regarding both eoFAD and sAD should be drawn with 
caution. 
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Time	  course	  of	  glucose	  metabolism	  and	  cognitive	  decline	  in	  PSEN1	  His163Tyr	  
and	  Met146Val	  mutation	  carriers	  
Glucose metabolism has not only been shown to be decreased in early pre-symptomatic 
stages of AD, it is also known to be closely related to cognitive decline and disease severity 
[179]. We followed one of the above-mentioned carriers of a His163Tyr mutation from 
age 46 to 57 – clinical diagnosis of AD was made at age 55 – and two carriers of a 
Met146Val mutation, one from age 41 to 43 (diagnosed with AD at age 39) and one from 
age 41 to 45 (diagnosed with AD at age 40), respectively (Papers I and II). 
 
 
Figure	  15.	  Decline	  in	  glucose	  metabolism	  in	  a	  PSEN1	  H163	  mutation	  carrier.	  
 
Longitudinal FDG PET and neuropsychological test data were compared with data from 
23 coeval healthy controls and 27 sAD patients who were on average approximately 25 
years older than the Met146Val mutation carriers at baseline. All mutation carriers showed 
global decrease of glucose metabolism when compared with the controls, but the regional 
patterns differed slightly between pre-symptomatic and symptomatic stages. 
 
	  
Figure	  16.	  Decline	  in	  glucose	  metabolism	  in	  a	  PSEN1	  M146V	  mutation	  carrier.	  
 
In the His163Tyr carrier, the most prominent early changes, besides the previously 
mentioned thalamic impairment, occurred in the posterior and anterior cingulate and 
frontal cortex, whereas parietal and temporal cortical as well as striatal metabolism 
decreased in later stages (Figure 15). The most pronounced decrease over time was 
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observed in the posterior cingulate cortex. Cognition was preserved until shortly before AD 
was diagnosed, when test results for episodic memory were deviant. Two years after the 
diagnosis, almost all cognitive domains were clearly impaired. A strong correlation was 
found between decline in posterior cingulate glucose metabolism and cognitive test scores 
for attention and cognitive speed (Digit Symbol Test, p<0.005) (Paper I). 
 Despite their young age and relatively short disease duration, both Met146Val 
mutation carriers had clearly decreased levels of glucose metabolism, globally, generally 
comparable with levels in the much older sAD patients, and significantly deviant cognitive 
performance. Here, decline was most prominent in the posterior cingulate, parietal and 
parietotemporal cortices, while frontal and temporal cortical as well as subcortical areas 
were somewhat more preserved over time. Global metabolic decline was statistically 
significant over time (Repeated Measure ANOVA corrected for multiple comparisons, 
α=0.05). The decline in global cognition correlated well mainly with decrease in CMRglc 
in the bilateral posterior cingulate (p<0.001) but also in the right parietotemporal cortex 
(p=0.05). 
 The regional pattern of decline in cerebral glucose metabolism observed in our 
studies fits well with what has been reported earlier in studies of individuals at risk for and 
suffering from eoFAD, MCI, and sAD [137, 180-183, 191, 192, 323]. In particular, 
glucose metabolism in the posterior cingulate cortex has been suggested to be a common 
reliable marker and predictor for cognitive decline from pre-symptomatic to early and late 
disease stages, whereas other typically affected brain regions might become impaired first at 
later symptomatic stages. 
	  
Relationship	  of	   regional	   glucose	  metabolism	  and	  post-­‐mortem	  pathology	   in	  
PSEN1	  Met146Val	  mutation	  carriers	  
The most characteristic post-mortem findings in the AD brain are neuritic plaques (NPs) 
and neurofibrillary tangles (NFTs) (see “Pathology and pathogenesis”). After having 
mapped the time course of glucose metabolism in PSEN1 Met146Val mutation carriers as 
described above, we aimed to explore the relationship between neuropathological 
hallmarks of AD and ante-mortem decreases in glucose metabolism in the same individuals 
(Paper II). The brains of the two aforementioned mutation carriers were subject to post-
mortem examinations in terms of quantification of NP and NFT pathology in reference to 
a large data set of 249 sAD patients that were classified as Braak stage VI [324] (Paper II). 
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Macroscopically, cortical thickness was significantly less in the mutation carriers than in 
the sAD patients. Microscopically, vast amounts of NPs, including mainly diffuse plaques 
in the putamen, and NFTs were found in almost all examined brain regions, exceeding the 
numbers seen in the sAD patients by far. NFTs were absent in the cerebellar cortex and the 
putamen in both eoFAD and sAD patients.  
 
	  
Figure	  17.	  Correlation	  between	  regional	  glucose	  metabolism	  and	  regional	  amounts	  of	  neuritic	  plaques	  
and	  neurofibrillary	  tangles	  in	  two	  PSEN1	  M146V	  mutation	  carriers.	  
 
The Met146Val mutation thus appears to be an eminently devastating eoFAD mutation, 
given the very early mean age of disease onset of about 38 years, the rapid decline in 
glucose metabolism (as described before), and the neuropathological picture presented 
here. APPswe mutation carriers with comparable disease duration had previously been 
shown to have comparable patterns of regional neuropathology to those in sAD patients 
[325], suggesting that PSEN1 mutations, or at least the one studied at hand, might cause 
earlier and more severe AD than the APPswe mutation. 
 CMRglc is commonly referred to as a marker for synaptic activity, involving 
metabolic processes in both neurons and astroglia (see "Glucose metabolism") and a 
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relationship with neuropathology is therefore likely. While both CMRglc and tau 
pathology correlate well with disease progression [32, 177] and thus with each other 
during disease development, this seems not to be the case when end-stage pathology is 
reached. In fact, a significant negative Spearman’s Rank correlation was observed in the 
mutation carriers between levels of right hemisphere regional CMRglc (rCMRglc) of the 
last ante-mortem FDG PET scan and the amount of NPs in the respective brain regions 
(n=15; Rho=−0.602; p<0.05), but not between rCMRglc and counts of NFTs (Figure 17). 
Several previous studies have reported similar lacking or poor correlations between cerebral 
tau pathology or CSF levels of tau and regional rCMRglc [326-329], whereof one showed, 
similar to our findings a strong relationship between rCMRglc and senile plaque load in 
one subject [329]. 
  Of note is that NFT pathology, consistent with the above-mentioned studies, was 
highly abundant in the hippocampus. This region was not included in the set of ROIs for 
FDG PET analysis. Moreover, there was a considerable time gap of five years between the 
last FDG PET scans and post-mortem examinations, hampering confident interpretation of 
our findings. 
  
PIB	   retention	   in	  APParc	  mutation	   carriers	   in	   relationship	   to	   AD	   biomarkers	  
compared	  with	  other	  eoFAD	  mutations	  and	  sAD	  
Among the eoFAD mutations, those located within the sequence encoding Aβ seem to 
have an exceptional position. Substitution or deletion of merely one base results in entirely 
different phenotypes and disease types. Two of these, the Arctic APP (APParc) and the  
E693Δ mutation, have been reported to favour Aβ oligomer and/or protofibril over fibril 
formation and to still cause a typical clinical picture of AD [95, 97, 330]. A post-mortem 
study in APParc mutation carriers who had suffered from Alzheimer-like dementia 
demonstrated ring-formed plaques without an Aβ core that stained negative for Congo red 
but positive for silver impregnation and C-terminal Aβ40/42 antibodies [98]. 
 We were interested in how this particular Aβ pathology would picture in vivo in 
terms of PIB PET retention in the context of other established biomarkers of AD and we 
performed as part of a larger longitudinal multi-tracer study on eoFAD and sAD the first 
in vivo examination of seven members, of whom two were mutation carriers, of a family 
harbouring the APParc mutation. For comparison, one carrier of the PSEN1 His163Tyr 
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mutation, one carrier of the APPswe mutation, as well as seven healthy controls (HCs) and 
seven sAD patients were included in the study. One APParc (APParc-1) and the 
His163Tyr mutation carrier (PSEN-1) had been diagnosed with AD, the subject with the 
APPswe mutation (APPswe-1) with MCI, and the second APParc mutation carrier 
(APParc-2) reported occasional subjective cognitive impairment but had not received a 
clinical diagnosis. 
 
	  
Figure	  18.	  PIB	  and	  FDG	  PET	  scans	  of	  seven	  healthy	  controls,	  the	  two	  carriers	  of	  the	  APParc	  mutation,	  
one	  PSEN1	  H163Y	  mutation	  carrier,	  one	  APPswe	  mutation	  carrier,	  and	  seven	  sAD	  patients.	  Of	  note	   is	  
the	  lack	  of	  PIB	  retention	  in	  the	  APParc	  mutation	  carriers.	  HCs:	  Healthy	  controls;	  sAD:	  Sporadic	  AD.	  
 
Both APParc mutation carriers presented with "negative" PIB PET scans, reflecting very 
low grey matter retention, comparable with the scans of their related mutation non-carriers 
and the healthy controls (Figure 18). This was despite otherwise clearly pathological CSF 
measures of Aβ1-42, t-tau, and p-tau (Figure 19). APParc-1 furthermore showed globally 
decreased glucose metabolism and significant atrophy in the hippocampus and entorhinal 
cortex in comparison with the HCs. APParc-2 revealed focally decreased glucose 
metabolism in posterior cingulate, temporal, and parahippocampal cortices, as well as in 
hippocampus, but no atrophy. PSEN-1 had been examined with PIB PET one year before 
(Paper 1), demonstrating high cortical PIB retention and especially elevated levels in the 
striatum. This pattern was basically unchanged on this occasion, with striatal PIB retention 
exceeding levels in sAD patients. CSF measures, global glucose metabolism, and 
hippocampal volume were significantly lower than in HCs. PIB retention was globally 
high also in APPswe-1 with levels in the striatum, thalamus, and hippocampus being 
higher than in sAD patients. CSF levels of Aβ1-42 and p-tau were pathological whereas 
glucose metabolism and brain structure were preserved. 
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Figure	   19.	   CSF	   data	   of	   all	   study	   participants.	   All	   eoFAD	  mutation	   carriers,	   including	   the	   two	  APParc	  
mutation	  carriers,	  showed	  pathological	  levels	  of	  Aβ1-­‐42	  and	  tau	  in	  CSF.	  
 
Elevated cortical levels of PIB retention have been reported in over 90% of patients with a 
clinical diagnosis of AD and are furthermore consistently found in early symptomatic and 
pre-symptomatic disease stages [297, 331]. Rare cases are known where a clinical picture of 
AD coincided with a lack of PIB binding, suggesting that a certain threshold of binding 
must be reached for detection with PET [222]. Patients with eoFAD also commonly show 
high PIB retention, often characterised by focally increased striatal binding already at early 
pre-symptomatic stages [226, 227]. PIB retention is also well known to be inversely related 
to CSF levels of Aβ1-42 [332, 333]. PIB has been proven to be a specific marker for 
extracellular and intravascular fibrillar Aβ structures, binding to the β-pleated sheet 
conformation of the Aβ fibrils [207, 208, 334, 335]. The plaques found in a post-mortem 
examination of APParc mutation carriers did not stain for Congo red or thioflavine-S, 
illustrating a lack of β-pleated sheet fibrils of Aβ [98]. 
 Our findings of negative PIB scans in the presence of low levels of CSF Aβ1-42 in 
APParc mutation carriers, who also showed characteristics typical of AD in other 
biomarkers, suggest that forms of Aβ other than mature β-sheet fibrillar forms can cause 
AD-type dementia. Since APParc promotes protofibril formation at high levels [97], these 
forms are likely to underlie the clinical picture of AD in our mutation carriers. This is 
supported by the recent discovery of the E693Δ mutation in the same amino acid positions 
as the APParc mutation, which causes recessively inherited AD type dementia by way of 
enhanced formation of Aβ oligomers [95]. Analogous to our results, PIB PET retention in 
symptomatic carriers of this mutation was very low while CSF levels of Aβ1-42 were 
pathologically low. 
HC
s
sA
D
AP
Pa
rc 
no
n-c
arr
ier
s
AP
Pa
rc-
1
AP
Pa
rc-
2
AP
Ps
we
-1
PS
EN
1-1
0
500
1000
1500
2000
pg
 / 
m
l
HC
s
sA
D
AP
Pa
rc 
no
n-c
arr
ier
s
AP
Pa
rc-
1
AP
Pa
rc-
2
AP
Ps
we
-1
PS
EN
1-1
0
200
400
600
800
1000
pg
 / 
m
l
HC
s
sA
D
AP
Pa
rc 
no
n-c
arr
ier
s
AP
Pa
rc-
1
AP
Pa
rc-
2
AP
Ps
we
-1
PS
EN
1-1
0
50
100
150
pg
 / 
m
l
Aβ1-42 T-tau P-tau
  54 
The pathological effects of Aβ oligomers and protofibrils have so far only been studied in 
vitro [39-45]. Our study might provide a link between these studies and clinical disease. 
Furthermore, it is important to mention that CSF Aβ1-42 and PIB retention in AD must 
not necessarily be inversely related, although this might be the case in the majority of sAD 
cases, which has already led to approaches to transform CSF Aβ1-42 levels into PIB 
retention [336]. 
 
Evidence	  for	  astrocytosis	  in	  prodromal	  AD	  
Neuroinflammation is a prominent feature in AD, mediated predominantly by microglia 
and astrocytes. Activated astrocytes have been found to gather predominantly around Aβ 
plaques and to play an important role in Aβ plaque formation and Aβ clearance [77, 79-
84]. The time course of astrocyte activation in the AD disease process is thereby still 
unknown. In order to explore the relationship between fibrillar Aβ pathology and 
astrocytosis and the underlying time course, we performed a multi-tracer PET study in 
MCI and mild AD patients in comparison with healthy controls, using 11C-L-deuterium-
deprenyl (DED) (see "PET in AD: Neuroinflammation"), PIB, and FDG PET (Paper IV).  
 The modified reference Patlak model we used for kinetic modelling of the DED 
data generates an intercept (tracer delivery) and a slope value (tracer binding). We found 
that the PIB+ MCI patients had the highest DED slope values in all examined cortical 
brain regions, somewhat less so in subcortical regions, whereas the AD patients presented 
with slope values generally comparable with those observed in the controls. Initial 
ANOVA, involving the undivided MCI patient group, revealed significant group effects in 
the frontal and parietal cortices. The intercept values followed the pattern HC>MCI>AD 
but did not differ significantly between the groups. Since MCI patients who show elevated 
PIB retention are commonly more likely to progress to AD than those with low levels 
[220, 337], we divided the MCI patients into PIB positive (+) and PIB negative (-), 
applying a previously defined cut-off. Subsequent statistics then revealed significant group 
effects of DED slope values now in the right occipital cortex and right hippocampus. The 
PIB+ MCI patients showed FDG and PIB PET measures comparable with those among 
the AD patients and were in an intermediate state between the PIB- MCI and the AD 
patients as regards cognitive test results and CSF measures. They could thus be regarded as 
cases of prodromal AD. 
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 Our finding of increased DED binding in MCI patients who are likely to develop 
AD suggests that enhanced MAO-B activity as a measure of astrocytosis is an early 
phenomenon in the disease process. This concept is supported by several observations. A 
recent autoradiography study using 11C-L-deprenyl in the brains of AD patients with 
different Braak stages found a distinct pattern of decreased binding with increased Braak 
staging with early stages (I-III) showing highest overall binding. Among the multitude of 
functions that astrocytes exert during neuroinflammation are many associated with Aβ. 
Hence, extracellular Aβ deposition has been shown to trigger astrogliosis [338] and 
astrocytes participate in the formation of Aβ plaques and in Aβ clearance [82-84, 339], 
both of which are processes likely to be enhanced at an early disease stage phenotypically 
represented by MCI. The question then arises is if astrocytosis should be regarded as a 
product or a producer of Aβ. MCI is also a state of early neurodegeneration as visualised, 
for example, by many MRI studies on brain atrophy and damaged or degenerating neurons 
are strong initiators of reactive astrocytosis [338]. Moreover, both neurons and astrocytes 
have been reported to undergo apoptosis in AD [340], possibly implying both less need for 
astrocytic support of neurons and astrocyte degeneration as an explanation for the 
decreased DED slope values observed in our AD patients.  
 Given the close relationship of astrocytosis and Aβ as well as the role that astrocytes 
are suggested to play in glucose metabolism, a correlation between DED binding and PIB 
and/or FDG signal could have been expected. However, no regional relationship was 
observed between any of the three tracers. This is in agreement with results of a recent 
study from our group that revealed a lack of relationship between in vivo 11C-PIB and 3H-
PIB binding versus 3H-L-deprenyl binding and in vivo FDG PET uptake versus 3H-L-
deprenyl binding at autopsy of the first-ever PIB examined patient [209]. Highest 3H-L-
deprenyl was thereby observed in the hippocampus. In vivo PIB retention and levels of 
post-mortem GFAP immunostaining did correlate, indicating that MAO-B activity is a 
marker for a specific, reactive type of astrocyte, while GFAP is rather unspecific. 
Furthermore, a recent study in an AD mouse model demonstrated astrocyte hyperactivity 
in a synchronised manner across a larger cortical network, amplifying focal Aβ deposition 
[341]. Aβ deposits catalysed thus astrocyte activation distant from the actual Aβ pathology, 
which fits with the observed lack of regional correlation between DED binding and PIB 
retention in our study. 
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Figure	  20.	  Representative	  DED	  slope	  parametric	  and	  PIB	  and	  FDG	  sum/pons	  images.	  The	  MCI	  PIB+	  
patient	  showed	  the	  highest	  diffuse	  cortical	  DED	  binding.	  
	  
The finding of increased DED binding early in AD is intriguing. Methodological 
considerations should, however, be taken into account. It is not totally clear to what extent 
MAO-B expression equals astrocyte activation, since MAO-B has also been found in 
serotonergic neurons. In addition, the DED signal as observed by PET examination is 
known to be strongly related to blood flow. When using this tracer, kinetic modelling is 
thus essential to account for the blood flow component. Without arterial input data, our 
modified reference Patlak approach can merely be considered as an approximation, in 
particular with regard to the fixed correction for specific binding in the reference region.  
 A recently published study, unlike our results, reported significant differences in 
DED retention between a group of healthy controls and AD patients and a regional 
correlation between DED and PIB retention [254]. On closer inspection, however, it 
became obvious that there was actually no difference between DED slope values in 
controls and AD patients. Both the reported differences in tracer retention and tracer 
relationship were based on a slope/intercept ratio. This measure, originally proposed by the 
author of this thesis, was meant to account for differences in blood flow between different 
individuals. In fact, the intercept values in the AD patients were 15% lower than in the 
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controls, accounting completely for the observed differences in slope/intercept ratio. This 
could mean that differences in brain perfusion might have been measured rather than 
actual tracer binding. The scientific value of this ratio is thus yet to be established.	  
 We are currently in the process of finalising the first cross-sectional phase of a large 
longitudinal multi-tracer PET study including members of families harbouring eoFAD 
mutations, and MCI and sAD patients. Preliminary analyses have confirmed a pattern of 
increased DED binding in early, pre-AD stages. Especially young pre-symptomatic eoFAD 
mutation carriers and, again, PIB+ MCI patients demonstrated the highest DED binding. 
Thorough analysis will show if there are clear temporal and spatial patterns in DED 
binding in eoFAD and sAD. 
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Concluding	  remarks	  &	  Outlook	  
The general intention of this work was to use multi-tracer PET to investigate different 
pathological characteristics of eoFAD and sAD at pre-symptomatic and symptomatic 
disease stages, in relationship to other biomarkers of AD and/or post-mortem pathology. 
 
The main findings outlined following the order of presented papers are: 
 A decline in glucose metabolism was shown subcortically, more specifically in the 
thalamus, in very early pre-symptomatic PSEN1 eoFAD mutation carriers and 
extended over time into regions typically affected in sAD. 
 Glucose hypometabolism preceded cognitive impairment by many years in PSEN1 
eoFAD mutation carriers. 
 The regional pattern of glucose hypometabolism correlated with neuritic plaque 
pathology, not neurofibrillary tangles, in severe PSEN1 eoFAD cases. 
 Carriers of the APParc mutation showed absence of cortical PIB retention at 
different disease stages although CSF measures of Aβ1-42 and tau together with 
FDG PET revealed clear progressing AD pathology. 
 Hippocampal and entorhinal cortical atrophy was only present in later disease 
stages in eoFAD mutation carriers. 
 Symptomatic PSEN1 and APPswe mutation carriers showed high cortical PIB 
retention, exceeding sAD levels predominantly in the striatum, and CSF measures 
of Aβ1-42 and tau, while glucose metabolism was preserved in the APPswe carrier. 
 MAO-B activity as a marker of astrocytosis was increased in prodromal AD 
whereas AD patients had MAO-B activity comparable to that in healthy controls. 
 Fibrillar Aβ deposition, glucose metabolism, and astrocyte activation showed no 
regional relationship. 
 
Several conclusions can furthermore be drawn from this thesis: 
 Astrocytosis might be most pronounced in early disease stages, according to 
preliminary data both in sAD and eoFAD 
 A clinical phenotype of AD can be caused by other than fibrillar, β-sheet forms 
of Aβ, supposedly by protofibrillar or oligomeric species. 
 CSF measures of Aβ1-42 do not necessarily correlate with PIB retention in AD. 
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 FDG PET is a reliable measure of disease severity in eoFAD, from very early 
pre-symptomatic to terminal disease stages. 
 Subjects with eoFAD mutations show great variations in age of onset, disease 
progression, and pathology, not necessarily compatible with sAD 
 
 
At this point, the author would like to elaborate on aspects that have come to special 
attention during the course of this thesis work. 
  
Amyloid 
The amyloid cascade hypothesis states that Aβ sooner or later aggregates into insoluble, 
neuritic plaques. Its revision in turn implied that Aβ toxicity is mediated by oligomeric 
species; this has so far only been confirmed in vitro. With our PIB PET study in APParc 
mutation carriers, we have established a connection between a mutation that enhances Aβ 
protofibril formation and a clinical phenotype of AD without the presence of classical 
neuritic plaque pathology. 
 
Amyloid and astrocytes 
The complexity of astrocytic functions and networks and their potential role in AD 
constitute an intriguing field of research. Astrocytes, amongst others things, are involved in 
memory functions, neuronal and synaptic support, and energy metabolism. Reactive 
astrocytes are commonly found around Aβ plaques in post-mortem tissue and Aβ is a major 
mediator of astrocyte activation. Our data suggest a lack of spatial relationship between 
fibrillar Aβ deposits and reactive astrocytes. However, we showed the highest DED 
binding in MCI patients who were likely to progress to AD. In this intermediate disease 
state, many factors might be able to trigger astrocyte activation. Degenerating neurons call 
for support, synaptic dysfunction needs increased effort, and ongoing Aβ production and 
accumulation triggers astrocytic activity distant from focal pathology via the astrocytic 
network [341]. Results from our ongoing longitudinal multi-tracer PET study will shed 
more light on the temporal pattern of astrocytic activation, Aβ pathology, and glucose 
metabolism in both eoFAD and sAD.  
 With regard to the use of PET in astrocyte research there are several issues to 
resolve. It is not completely understood to what extent MAO-B activation as visualised by 
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DED PET actually represents reactive astrocytes since this enzyme is also expressed 
elsewhere in serotonergic neurons. Combining DED PET with PET using tracers for e.g. 
serotonergic receptors or the S100 protein, for example, might help to elucidate this issue. 
The understanding of what "reactive astrocyte" actually embraces is also fragmentary. It 
might be possible, though completely theoretical, that astrocytes can adopt different states 
of activation and that increased MAO-B activation reflects just a certain activation phase or 
even just a certain type of astrocytes. 
 Of great interest would also be more investigation of the role of astrocytes in 
cerebral glucose metabolism, especially with regards to FDG PET scanning. 
 
EoFAD and sAD 
EoFAD is commonly proposed as a model for AD. Two recent reviews attempted to 
summarise characteristics of known eoFAD mutations, reporting generally good 
compatibility of eoFAD with sAD in terms of clinical outcome, even though many eoFAD 
mutations show deviant characteristics that are not directly related to dementia [99, 342]. 
Most of the so far examined mutations do show comparable pathology post-mortem, but 
the roads there may differ greatly and the large and growing number of different eoFAD 
mutations complicates drawing universal conclusions. The author is reluctant to consider 
the idea that eoFAD could be regarded as a general model for sAD. Pure genetic causes of 
AD, shifting the age at onset in certain cases down to hardly more than 30 years, strongly 
imply different pathogenesis in comparison with sAD. It is, however, self-evident that it 
remains quite feasible to study certain disease mechanisms that are common in eoFAD and 
sAD and the author is convinced that particularly in vivo studies of eoFAD are an 
emerging and highly important field aspect of AD research. 
 However, studies in eoFAD always involve an ethical dilemma. Strategies and 
action plans regarding how to deal with the discovery of pre-symptomatic eoFAD 
mutation carriers, especially among the young, are urgently needed. This concerns also 
potential early, pre-symptomatic treatment strategies. 
 
Multi-tracer PET 
The author believes strongly in the potential of the multi-tracer PET approach. No other 
technique offers comparable possibilities of studying molecular processes in living humans 
and it has by that provided essential insights in disease mechanisms. The current portfolio 
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of available PET tracers with application in AD is impressive, yet the author is looking 
forward to the introduction of reliable and specific tracers for tau pathology, which would 
certainly contribute to the power of this collection. On the personal wish list is 
furthermore a study combining tracers for microglia and astrocyte activation. 
 
Proposal for time course 
As a general conclusion, based on findings in this thesis and in the context of previous 
studies mentioned in the Introduction, a modified hypothetical model for the time course 
of biomarkers of AD is proposed. The findings in this work are based on studies in groups 
with small numbers, sometimes even on an individual level. The presented conclusions are 
thus suggestions for potential facts. 
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